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ABSTRACT 
ROLE OF FAM134B IN LIVER CANCER 
Ayşe Derya Soner 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August 2013, 74 Pages 
 
The family with sequence similarity 134, member B (FAM134B) protein initially 
caught attention in our laboratory through demonstrating elevated levels possibly 
associated with senescent, cirrhotic, and mesenchymal-like states in hepatocellular 
carcinoma (HCC), and the aim of this thesis work was to identify the role of 
FAM134B in HCC.  The work in this thesis initially demonstrated that the induction 
of endoplasmic reticulum (ER) stress in normal mice livers with 8 hours of 
tunicamycin treatment did not significantly alter the levels of FAM134B mRNA or 
protein.  We then demonstrated that induction of ER stress in four HCC cell lines 
using several ER stress inducers such as thapsigargin, tunicamycin or DTT did not 
cause a significant increase in the levels of FAM134B mRNA or protein, with the 
exception of high dose DTT treatment of Snu449 cells which also demonstrated 
apoptosis.  We also observed that FAM134B protein levels may be elevated during 
epithelial-to-mesenchymal transition (EMT) in PLC cells induced by TGF-β 
treatment.  Snu449 cells in which FAM134B was silenced demonstrated an altered 
morphology in cell culture, and appeared to lose their migratory capabilities.  Most 
significantly though, FAM134B-silenced Snu449 cells demonstrated a dramatic loss 
of resistance to treatment with thapsigargin and adriamycin, which are both known to 
inhibit the calcium pumps on the ER.  The knockdown cells also demonstrated loss 
of resistance to serum starvation, TGF-β treatment, tunicamycin and alcohol 
treatment, but no significant difference was observed in resistance to 5-FU, 
camptothecin and hydrogen peroxide.  These results implicated that FAM134B may 
play a role that is essential for survival under several forms of cytotoxic threat, 
especially those that disturb calcium homeostasis.   
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ÖZET 
FAM134B’NİN KARACİĞER KANSERİNDEKİ ROLÜ 
Ayşe Derya Soner 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 2013, 74 Sayfa 
 
FAM134B (family with sequence similarity 134, member B) isimli protein 
laboratuarımızda ilk olarak seviyelerinin artışı hepatosellüler karsinomda hücre 
yaşlanması, siroz ve mezenkimal benzeri davranış durumları ile bağlantılı olabilecek 
bir protein olarak dikkat çekti, ve bu tez çalışmasının amacı FAM134B’nin 
hepatosellüler karsinomdaki rolünü tanımlamaktı.  Bu tezdeki çalışmalar ilk olarak 
normal fare karaciğerinde 8 saatlik tünikamisin uygulamasi ile indüklenen 
endoplazmik reticulum (ER) stresinin, FAM134B mRNA ve protein seviyelerine 
önemli bir etkisi olmadığını gösterdi.  Daha sonra da tapsigargin, tunikamisin ve 
DTT gibi indukleyiciler kullanılarak oluşturulan ER stresinin dört hepatosellüler 
karsinom hücre hattında da FAM134B mRNA ve protein seviyelerine önemli bir 
etkisi olmadığını gösterdik; tek istisnai durum yüksek doz DTT uygulanan ve hücre 
ölümü gösteren Snu449 hücreleri idi.  Bunların yanısıra, FAM134B protein 
seviyelerinin PLC hücrelerinde TGF-β ile indüklenen epitel-mezenkimal geçiş 
sırasında da artıyor olabileceğini gözlemledik.  FAM134B’nin susturulduğu Snu449 
hücrelerinin kültürde farklı bir morfolojiye sahip olduklarını, ve hareket 
kabiliyetlerini yitirdiklerini gözlemledik.  Fakat en önemlisi, FAM134B’nin 
susturulduğu Snu449 hücreleri, tapsigargin ve adriamisin uygulamasına olan 
dirençlerini çok ciddi bir şekilde kaybettiler, ve bu iki ilacın da ER membranındaki 
kalsiyum pompalarının çalışmasına engel oldukları biliniyor.  FAM134B’nin 
susturulduğu hücreler aynı zamanda serum yetersizliği, TGF-β, tunikamisin ve alkol 
uygulamalarına olan dirençlerinde de kayıp gösterdiler, fakat 5-FU, camptotesin ve 
hidrojen peroksite olan dirençlerinde ciddi bir değişim gözlenmedi.  Bu sonuçlar, 
FAM134B’nin hücre ölümüne neden olabilecek (özellikle de kalsiyum dengesinin 
bozulması gibi) birçok durumda hücrenin hayatta kalma mekanizmasında önemli bir 
rol oynayabileceğini gösteriyor. 
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1. INTRODUCTION 
1.1 Cancers of the Liver; Status Worldwide & in Turkey 
Cancer is a leading cause of death worldwide, and although the most common 
incidences are cancers of the breast, prostate and lung, liver cancers draw attention 
with the second poorest survival rates, preceded only by cancers of the pancreas, as 
shown in Figure 1.1 [1] .  
Figure 1.1: Mortality-to-incidence ratios of cancers in Turkey and Worldwide. 
Data obtained from GLOBOCAN 2008 Cancer Fact Sheet  [1] 
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As demonstrated in Figure 1.1, 93% of liver cancer patients do not survive this 
disease, while this ratio is 86% for lung cancers, and 33 and 29% for cancers of the 
breast and prostate respectively.  These high fatality rates make liver cancer the third 
most common cause of death from cancers worldwide, causing 600,000 deaths per 
year, although it is the seventh most common type of cancer [2] [3].   
These poor survival rates associated with cancers of the liver are caused by 
difficulties in timely diagnoses and inoperability of the tumors; most cases are 
diagnosed when the tumor has passed the localized state and reached the distant 
stage, [4] and only 10-20% of the tumors can be removed completely by surgery  [5].  
For the time being, the best treatment for liver cancer is liver transplantation, but it 
can be offered only to patients with small tumors and is limited by the availability of 
organ donors [6]. The prognostic outcome is better in more developed countries 
where more advanced facilities are available for both diagnosis and treatment [3].    
A significant ratio of liver cancers is attributable to infection by hepatitis B virus 
(HBV), for which vaccination is available; the ratio of liver cancers caused by HBV 
infection is 60% in developing countries and 23% in developed countries [3].  The 
World Health Organization is promoting a vaccination program, and 177 countries 
have integrated the HBV vaccine to their national infant immunization schedules as 
of 2008 [3].  Hepatitis C virus (HCV) infection, on the other hand, accounts for 33% 
of liver cancers in developing countries and for 20% in developed countries, 
however, vaccination is not possible thus far [3].  
Importantly, despite the implementation of preventative measures such as 
vaccination programs, the incidence rates of liver cancers are still increasing in many 
regions, including Central Europe and the United States, and this increase is partly 
attributable to the increasing rates of obesity [3].   
This worrying state draws attention to the mechanisms involved on the contribution 
of obesity and other non-viral factors on the onset and progression of cancers of the 
liver; obesity, metabolic syndrome, diabetes, exposure to aflatoxins, and alcohol 
consumption constitute an aspect of liver cancers for which the endoplasmic 
reticulum (ER) appears to play key roles, and these will be discussed in detail.   
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Figure 1.2 Histopathological progression and molecular features of HCC. [12] 
1.2 Hepatocellular Carcinoma  
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, making 
up 70% to 85% of all primary liver cancers worldwide [3].  Rarer forms of liver 
cancer include hepatoblastoma, angiosarcoma or cholangiocarcinoma [7].   
The liver is one of the major secretory organs of the human body, and hepatocytes 
constitute approximately 80% of the total mass of this organ; these cells are the main 
functional cells of the liver, and have essential roles in the synthesis and storage of 
many proteins, the metabolisms of carbohydrates and lipids, synthesis phospholipids, 
cholesterol and bile salts, and detoxification of drugs and toxins  [8].  
Both the dedifferentiation of mature hepatocytes and imperfect differentiation of 
hepatic progenitor cells (HPCs) appear to contribute to hepatocarcinogenesis [9] 
during the attempt of the liver to make up for hepatocytes lost by persistent damage; 
the mechanisms involved will be discussed in further detail. 
1.3 Pathogenesis of Hepatocellular Carcinoma 
 
Risk factors leading to hepatocarcinogenesis include viral infections such as 
Hepatitis B (HBV) and Hepatitis C (HCV) infections, metabolic conditions such as 
obesity, non-alcoholic fatty liver disease and diabetes, toxic factors such as alcohol 
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and aflatoxins, as well as other factors such as autoimmune hepatitis and hereditary 
haemochromatosis [10][11][12].  These factors can directly cause DNA damage, 
mutations and epigenetic irregularities involving oncogenes and tumor suppressor 
genes, telomerase activation and chromosomal abnormalities.  Moreover, persistent 
damage to hepatocytes also contribute to carcinogenesis through causing hepatocyte 
death either via apoptosis or via necrosis, which, in turn, leads to the development of 
chronic liver disease, fibrosis, and cirrhosis [13].  It is important to note that 80% of 
HCC cases are observed in patients that initially experience chronic liver disease and 
cirrhosis [14]. 
As a way to make up for cell death, the liver cells start regenerating, and this 
involves high rates of cell division and proliferation.  As demonstrated in Figure 1.2, 
this high rate of proliferation leads to telomere shortening and genomic instability 
[12].  The high rates of DNA replication may also make the cells more prone to 
errors and the accumulation of mutations.   
Most frequently reported molecular causes of aberrant proliferation and 
dedifferentiation of hepatocytes include; inactivation of tumor suppressors such as 
p53, retinoblastoma protein (pRb) or the p14
ARF
 and p16
INK4a
 proteins encoded by the 
CDKN2A gene, overexpression of oncogenes such as CyclinD1/Cdk4, insulin-like 
growth factor-II or c-MET, and activation of Ras/mitogen activated protein (MAPK), 
transforming growth factor-β (TGF- β) or Wnt/ β-catenin signaling cascades [15]. 
1.3.1 Fibrosis as an Initial state of Hepatocarcinogenesis 
Damage to hepatocytes may be caused by several factors such as elevated metabolic 
overload resulting in high levels of reactive oxygen species (ROS) and ER stress, 
chemical toxicity by drugs, alcohol or aflatoxins, or viral activity causing metabolic 
deregulation [16].   
Steatosis, which involves the expanding of hepatocytes due to excessive lipid droplet 
storage, is one of the first signs of cellular stress, and is highly reversible.  
Irreversible or persistent damage, however, may cause hepatocyte death through 
apoptosis or necrosis. The death-mediated signals trigger the activation of Kupffer 
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and quiescent hepatic stellate cells which coordinate an inflammatory and wound 
healing response; Kupffer cells are specialized macrophages of the liver, and stellate 
cells are pericytes involved in formation of scar tissue. As illustrated in Figure 1.3, in 
an acute setting, this response might lead to tissue regeneration and repair, however, 
when the injury is chronic, the consequences are fibrogenesis, cirrhosis, and cancer 
[13]. 
 
 
 
 
 
 
 
 
 
 
 
Fibrosis is the scarring of a tissue due to excessive deposition of extracellular matrix 
(ECM) proteins as an attempt of repair.   During chronic liver injury, the quiescent 
hepatic stellate cells become activated by signals described in Figure 1.4, such as 
inflammatory cytokines and give rise to myofibroblasts.  Myofibroblasts are the cell 
type responsible for fibrosis in the liver [13]. 
As also shown in Figure 1.4, transforming growth factor-β (TGF-β) is considered one 
of the major pro-fibrogenic cytokines, as demonstrated by data obtained from animal 
models of liver damage [13].  In fact, TGF-β plays important roles in many stages of 
liver disease, which will be discussed in detail.  
Figure 1.3: The progression of hepatocellular carcinoma & the role of senescence as a means of 
eliminating fibrotic cells. Adapted from Dooley & Ten Dijke, 2012 [13] 
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Figure 1.4: Molecular mechanisms involved in activation of hepatic stellate cells, fibrosis, and 
perpetuation into a tumorigenic form. 
Friedman, 2010 
Although majority of evidence suggests that hepatic stellate cells are the main 
contributors of the myofibroblast build that forms during fibrogenesis, there is 
evidence that other cell types such as portal fibroblasts of the liver, bone-marrow-
derived fibrocytes, or circulating mesenchymal cells may also contribute to the 
fibrosis through deposition of extracellular matrix proteins [13] [17].   
 
Interestingly, some research also indicates that hepatocytes and biliary epithelial cells 
may also contribute to myofibroblast formation during fibrosis of the liver.  
Hepatocytes and biliary epithelial cells of the liver may transdifferentiate into 
myofibroblasts through epithelial-to-mesenchymal transition (EMT, which will be 
explained later in detail) that may be mediated by TGF-β, Hedgehog and bone 
morphogenic protein 7 (BMP7), and contribute to ECM deposition and fibrosis [17].  
Unlike the later stages of cirrhosis, fibrosis of the liver is a state that can be resolved, 
either through reversal of the fibroblastoid morphology by mesenchymal-to-
epithelial transition (MET) [17], or through the elimination of fibrotic cells by 
senescence and apoptosis [13]. 
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1.3.2 Senescence and Hepatocarcinogenesis   
Senescence is a term that describes the process of becoming old, and cellular 
senescence is a phenomenon characterized by permanent cell cycle arrest [14]. 
Senescence can be identified by markers such as senescence-associated DNA-
damage foci, senescence-asssociated heterochromatin foci, senescence-associated β-
galactosidase (SABG) and p16
INK4A
 [14].   
Senescence can be inspected in three pathways; telomere-dependent senescence, 
oncogene-induced senescence, and ROS-induced senescence.  All three of these 
pathways lead to senescence by triggering a DNA damage response in the cell (often 
induced by double strand breaks in the DNA), which activates ATM and ATR 
kinases, leading to the phosphorylation of p53 by CHK1 and CHK2 kinases.  
Phosphorylated p53 is released from MDM and stabilized, and can then induce 
senescence or apoptosis [14].  The form of senescence that is dependent on telomere 
shortening is also known as “replicative senescence” since telomere length acts as a 
cell-division counter in this case, as will be described in detail [14]. 
This cell cycle arrest, followed by apoptosis, may act as a barrier to the progression 
of HCC by acting as a means of eliminating fibrotic cells [13].  Senescent cells are 
observed at a ratio of 10% in normal liver, which is elevated to 84% in cirrhosis, and 
is reduced to 60% in HCC.  These rates of senescence are mainly attributable to 
replicative senescence dependent on telomere shortening of hepatocytes.  It was also 
observed that senescence-inducing proteins such as p16
 INK4a
 and p21
Cip1
 accumulate 
in cirrhotic livers.  Senescence-escape mechanisms such as telomerase reactivation, 
or mutations or epigenetic silencing events in senescence-inducing genes such as p53 
and p16
INK4a
 play important roles in the progression of HCC [14].   
1.3.2.1 Telomere Shortening & Telomere-Dependent Senescence 
Human chromosomes contain DNA-protein complexes named “telomeres” at the 
ends of each chromosome.  Since DNA replication cannot initiate from the very ends 
of linear DNA, important genetic information would be lost by each replicative cycle 
without the availability of the TTAGGG telomere repeats at the ends of the 
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chromosomes. Therefore, the telomeres prevent genomic instability and the loss of 
essential genetic information by forming a cap at the ends of the chromosomes [14]. 
Majority of human somatic cells are incapable of synthesizing new telomeres due to 
the repression of telomerase reverse transcriptase (TERT) expression, therefore, 
telomeres become shorter with every cycle of cell division, acting as a “cell cycle 
counter” which helps determine when the cell should stop replicating.  Shortened 
telomeres begin to lose their protected status, and such loss of telomere protection or 
any other form of telomere dysfunction leads to the formation of abnormal 
chromosomal end-to-end fusions through non-homologous end joining or 
homologous recombination pathways of DNA repair.  The triggering of these DNA 
repair pathways indicate that open-ended telomere DNA is recognized as double 
strand breaks.  This triggers a DNA damage response in the cell, which leads to 
senescence through the phosphorylation of p53, as previously mentioned, which 
activates p21
cip1
, which is an inhibitor of Cyclin-dependent kinase 2 (CDK2).  These 
events keep the tumor suppressing pRb protein in the active form, inhibiting E2F 
function and the expression of growth-promoting genes [14]. 
1.3.2.2 ROS-induced and Oncogene-induced Senescence 
Reactive oxygen species (ROS) are mostly produced during cellular respiration at the 
mitochondria.  In vitro methods of ROS induction such as mild H2O2 treatment and 
culturing under high O2 conditions were shown to induce or aggravate senescence 
and cause reduced lifespans.  ROS and oxidative stress may give rise to senesce 
through causing DNA damage or inducing changes in other signaling pathways  [14]. 
Senescence has also been observed in response to the expression of well-studied 
oncogenes such as Ras, Raf, Myc, Cyclin E, Mek and Mos.  In the case of Ras, 
expression of this oncogene was demonstrated to cause G1 arrest together with 
elevated levels of cell-cycle arrest associated proteins such as p53 and p16
INK4a
 [14]. 
These two forms of senescence, like telomere-dependent replicative senescence, 
work primarily through DNA damage response pathways as well, but they can also 
induce other signals that lead to the activation of cyclin-dependent kinase inhibitors 
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such as p16
INK4a  
and p15
INK4b
 that inhibit CDK4 and CDK6 to keep the tumor 
suppressing pRb protein active [14] 
1.3.3 Cirrhosis  
As mentioned earlier, 80% of HCC cases originate as chronic liver disease and 
cirrhosis [14].  Although often mistakenly considered simply as an extended form of 
fibrosis, cirrhosis is, in fact, different from fibrosis in many ways.  Cirrhosis is 
characterized by extensive inflammatory signaling, architectural disruption of the 
tissue due to excessive secretion of ECM proteins by myofibroblasts originating from 
stellate cells, aberrantly regenerating or senescent hepatocytes, nodule formation and 
vascular changes, and is often not reversible [13] [14].  
 
1.4 Epithelial to Mesenchymal Transition and TGF-β 
Epithelial cells of the adult human have a distinct apical-basal cell polarity, are often 
in layers of cells that are held together by cell-to-cell adhesion proteins such as E-
cadherin, form a sheet on a basement membrane, and are immobile.  Organs of the 
human body are often made up of organized, immobile epithelial cells that may 
mainly carry out secretory functions as in the cases of the liver and the pancreas.   
Mesenchymal cells, on the other hand, have very different phenotypes; they do not 
express E-cadherin, and are therefore not organized in layers having polarities, and 
they can migrate easily.  Mesenchymal stem cells of the adult human reside in the 
bone marrow, and give rise to the highly mobile cells of the circulatory and 
lymphatic systems, as well as bone and cartilage tissues [18]. 
Epithelial to mesenchymal transition (EMT) is the reversible change of an epithelial 
cell into a mesenchymal or, in some cases, fibroblastoid phenotype.  Epithelial cells 
that undergo EMT assume a more mesenchymal phenotype, losing their cell polarity 
and cell-to-cell adhesion characteristics and gaining the ability to transmigrate the 
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basement membrane and connective tissues to move into circulation, and becoming 
motile and invasive [15]. 
This switch from an epithelial to a mesenchymal phenotype is a normal part of 
embryonic development.  It initially occurs during the gastrulation stage of the 
blastula, forming the mesoderm which gives rise to mesenchymal cells that 
contribute to extraembryonic tissues. Later in development, EMT contributes to the 
development of the circulatory, nervous and musculoskeletal systems [15]. 
In the adult, however, EMT usually occurs under pathophysiological circumstances 
such as chronic inflammation, wound healing response, and cancer progression.  
During wound healing, epithelial cells obtain reduced adhesiveness and increased 
migration capabilities during the process of producing new and intact epithelial 
layers.  EMT is also observed during the non-regenerative repair attempt of an organ 
called fibrosis, which includes the dedifferentiation of epithelial cell types into a 
more fibroblastoid phenotype, contributing to the wound healing and inflammation 
response by secreting ECM proteins, and this event has been demonstrated to take 
part in liver fibrosis as well [15]. 
Transforming growth factor-β (TGF-β) is a cytokine that functions through Smad2/3 
and Smad4 to control gene transcription and induce cellular effects such as growth 
inhibition, apoptosis, differentiation and extracellular matrix deposition [19].  The 
ultimate result of TGF-β signaling depends on the activities of other pathways in the 
cell, such as Ras signaling, and can have complex effects, as will be described.  
1.4.1 Epithelial to Mesenchymal Transition and TGF-β in Liver Fibrosis 
EMT has been demonstrated to participate significantly in liver fibrosis, with major 
contributions from the cytokine TGF-β.  The first evidence that hepatocytes give rise 
to fibroblasts by going though EMT during liver fibrosis was provided by a study 
where EMT was induced in mouse hepatocytes by treatment with TGF-β1, and the 
hepatocytes were observed to change into fibroblast-specific-protein (FSP)-1 positive 
hepatic fibroblasts [20].   Another research study demonstrated that hepatocytes 
isolated from cirrhotic livers, which had been exposed to elevated levels of TGF-β in 
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vivo, had elongated, fibroblastoid-like phenotypes and expressed vimentin and 
collagen I  [21].   Further research demonstrated that loss of epithelial phenotype in 
primary mouse hepatocytes in response to TGF-β treatment was associated with 
upregulation of SNAIL and consequent loss of E-cadherin expression[22] and that 
this also involved the activation of Smad2/3 signaling and collagen I synthesis [23].   
Also very interestingly, it was demonstrated that EMT in primary murine 
hepatocytes was associated with FAK/Src dependent activation of the PI3K/Akt 
signaling, which causes resistance to apoptosis, as well as Erk1/2 signaling, which 
causes induction of EMT, demonstrating that EMT confers resistance against TGF-β-
induced apoptosis [24].  This observation may be of particular interest to this study, 
as the Akt/Erk pathway is known to play key roles in cell survival under ER stress 
[25], for which the protein studied here, FAM134B may also play key roles, as will 
be discussed later in detail.  
1.4.2 Epithelial to Mesenchymal Transition and TGF-β in the progression of 
Hepatocellular Carcinoma 
TGF-β and EMT appear to play dual roles during the progression of hepatocellular 
carcinoma; in the healthy liver and during tumor initiation through fibrosis, TGF-β 
appears to induce cell cycle arrest, apoptosis and the development of a fibroblastoid-
like phenotype, and at the neoplastic stage, TGF-β controls dedifferentiation and 
spreading of the neoplastic hepatocytes, contributing to the development of a poorly-
differentiated state and metastatic behavior. [15] 
Murine tumor models have demonstrated that a synergy between oncogenic Ras and 
TGF-β1 signaling causes EMT, malignant progression and metastasis, and that these 
are associated with loss of E-cadherin and the tight junction protein ZO-1, and 
activation of Smad2/3 leading to autocrine TGF-β signaling.  Further studies showed 
that the induction phase of EMT requires crosstalk between TGF-β and MAPK, and 
that the maintenance phase depends on the activation of PI3K/Akt. EMT was also 
shown to be associated with increased platelet-derived growth factor (PDGF) 
signaling, independent of the genetic background of EMT, which was demonstrated 
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to cause migration and tumor progression. Interleukin-like EMT inducer (ILE1), 
which is a downstream target of TGF-β signaling, was shown to collaborate with 
oncogenic Ras to trigger the activation of STAT3, as well as the nuclear 
accumulation of β-catenin, via PDGF/ PDGF-R. [15] 
Human studies were also supportive of the previous findings; studies with HCC cell 
lines revealed that elevated expression of the ECM protein laminin (Ln)-5 leads to 
the activation of Erk1/2, which is required for cell proliferation.  In patient studies, 
58% of HCC cases demonstrated reduced levels of E-cadherin.  Loss of E-cadherin 
in HCC patients was reported to be accompanied by loss of β-catenin from cell 
borders and partial translocation to nucleus, as well as elevated levels of the ECM 
protein Laminin-5.  Loss of E-cadherin also significantly correlated with intrahepatic 
metastasis and poor survival of patients.  Also, expression of Twist, a negative 
regulator of E-cadherin expression, in non-metastatic HCC cells induced EMT and 
increased invasion. Also interestingly, viral proteins of HCV were also observed to 
render hepatocytes less sensitive to anti-proliferative effects of TGF-β. [15] 
 
1.5 The Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is an organelle made up of a membrane-enclosed 
network of sacs, with central roles in protein and lipid synthesis, membrane 
biogenesis, xenobiotic detoxification, cellular calcium storage and the proper folding 
and modifying of proteins [26]. The ER membrane makes up more than half of the 
total membrane area of an animal cell, and is the production site of all 
transmembrane proteins in a cell, including those of the membrane-bound organelles 
and the plasma membrane.  And the ER lumen is where almost all of the secretory 
proteins and proteins of the ER lumen itself, the Golgi apparatus and lysosomes are 
delivered for processing, folding and modifications.  [27] 
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1.5.1 The Abundance and Functions of Rough and Smooth ER in Hepatocytes  
Hepatocytes are the major providers of glucose and lipids to the entire human body, 
and they can produce millions of proteins per minute, possessing one of the highest 
rates of protein synthesis in the human body, and the overwhelming majority of these 
proteins are processed in the ER.  [28] 
The rough ER, which contains ribosomes on the cytosolic face, is mainly concerned 
with protein synthesis, and is abundant especially in cells that secrete proteins, for 
example, in hepatocytes that secrete proteins such as serum albumin or coagulation 
factors, or pancreatic β-cells that are responsible for insulin secretion.  Most proteins 
synthesized in the rough ER are N-glycosylated and are destined for transport to the 
plasma membrane, Golgi apparatus, lysosomes or extracellular space, while proteins 
destined for the cytosol are often not glycosylated.  Ca
2+
 dependent chaperones such 
as calnexin retain incompletely folded proteins in the ER until they are properly 
folded, depending on their N-glycosylation status. [27] 
The smooth ER, on the other hand, lacks ribosomes, and is mainly concerned with 
lipid metabolism, carbohydrate metabolism, and detoxification.  Smooth ER is very 
abundant in hepatocytes since these cells play key roles in lipid and carbohydrate 
metabolism, and are responsible for producing lipoprotein particles and detoxifying 
lipid-soluble drugs and metabolic byproducts.  During detoxification of drugs or 
toxins such as phenobarbital or ethanol, the smooth ER of hepatocytes can double its 
surface area within a few days in order to be able to synthesize the unusually large 
amounts of detoxification enzymes required.  [27] 
Another fundamental responsibility of the ER is to store Ca
2+
; the release and uptake 
of Ca
2+
 to and from the cytosol is involved in many rapid responses to extracellular 
signals, [27] and is involved in timing of the exocytosis of synthesized proteins, such 
as the release of insulin by pancreatic β-cells.  The ER membrane contains an ATP-
dependent channel that pumps Ca
2+
 from the cytosol into the ER lumen, generally 
named as sarco-endoplasmic reticulum Ca
2+
 ATPases (SERCA).  
Calcium homeostasis is especially important for liver cells; Hotamisligil et al. have 
recently reported its implications in obesity by demonstrating that aberrant lipid 
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metabolism disrupts calcium homeostasis and causes liver endoplasmic reticulum 
stress in obesity [26].  Furthermore, recent research has shown that Ca
2+
 gradients are 
also important for the coating and uncoating of transport vesicles that are trafficked 
between the ER and the Golgi apparatus [29]. 
1.5.2 Endoplasmic Reticulum Stress and the Unfolded Protein Response 
A sudden high demand of protein synthesis, inducers of oxidative stress, or some 
other disruption of ER homeostasis can cause the accumulation of misfolded proteins 
in the ER, and this triggers the unfolded protein response (UPR).  The accumulation 
of unfolded proteins in the ER is sensed by the binding immunoglobulin 
protein/glucose-regulated protein 78 (BiP/GRP78).  Upon being sequestered by 
misfolded proteins, BiP/GRP78 dissociates from the three known ER-membrane 
transducers, inositol requiring 1α (IRE1α), PKR-like ER kinase (PERK), and 
activating transcription factor 6α (ATF6α), allowing their activation.  These three 
transducers initiate a response that aims to alleviate ER stress by reducing the load of 
new peptides entering the ER, increasing the folding capacity of the ER and 
degrading misfolded proteins. [30] 
PERK phosphorylates eukaryotic initiation factor 2 alpha (eIF2α), which attenuates 
global mRNA translation, aiming to alleviate some of the peptide burden on the ER.  
PERK also selectively increases the translation of ATF4, which is a transcription 
factor that induces the expression of chaperones, amino acid transporters, antioxidant 
stress response genes, ER-associated degradation (ERAD) proteins and C/EBP 
homologous protein (CHOP), which can cause apoptosis if ER stress persists. [30]  
IRE1α has kinase and RNAse activities; its autophosphorylation activates the RNase 
activity to splice X-box binding protein 1 (XBP1) mRNA, allowing the production of 
the active transcription factor sXBP1.  sXBP1 upregulates ER chaperones, ERAD 
proteins, and CHOP. IRE1a activation also facilitates mRNA degradation and 
translation attenuation, in collaboration with PERK.  IRE1α also recruits and 
activates C-jun N-terminal kinase (JNK), which is a stress kinase that can mediate 
apoptosis under persistent ER stress. [30] 
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ATF6α released from BiP/GRP78 transports to the Golgi apparatus, where it is 
cleaved and activated by intramembrane proteolysis.  The activated transcription 
factor ATF6α heterodimerizes with and activates sXBP1 to induce the transcription 
of chaperones, ERAD proteins and CHOP. [30] 
Unresolved ER stress results in apoptosis through mechanisms involving CHOP, 
JNK, Bcl-2 family proteins, calcium and redox homeostasis, and caspase activation 
[30].  For instance, apoptosis induced by ER stress has been shown to involve 
disruption of calcium homeostasis and protein accumulation, which leads to the 
calpain-mediated activation of caspase-12, which is localized to the ER [31].  In fact, 
disruption of calcium homeostasis appears to be very important for the link between 
ER stress and apoptosis. Overexpression of the anti-apoptotic protein Bcl-2 was 
shown to reduce free ER calcium and cell death, while reduction of the pro-apoptotic 
proteins Bak and Bax resulted in lower free ER calcium and reduced sensitivity to 
apoptotic stimuli such as hydrogen peroxide treatment. [30] 
1.5.3 Endoplasmic Reticulum Stress, Obesity and Liver Disease 
Hepatocytes, pancreatic exocrine cells and adipoctyes constitute a triad of cells that 
have very important metabolic functions, have high protein synthesis rates, and are 
therefore very sensitive to ER stress brought on by disruptions of metabolic 
homeostasis, such as excess nutrients, insulin peaks, and obesity.  [28] 
Obesity is a risk factor for non-alcoholic fatty liver disease, type 2 diabetes, and 
hepatocellular carcinoma, which are all interconnected.  In mouse models, obesity 
has been demonstrated to induce ER stress in liver and adipose tissues of mice.  A 
high demand on adipocytes to store more lipids than they can handle causes 
production of reactive oxygen species (ROS), inflammation, ER stress, apoptosis, 
and increased fatty acid (FA) release.  The excess circulating FAs are taken up by the 
liver, and cause a lipotoxicity that alters glucose utilization and insulin action, and 
results in steatosis of hepatocytes. In the livers of obese mice, ATF6α expression was 
observed to be reduced, and its reconstitution was observed to improve glucose 
homeostasis. [32] 
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The UPR influences metabolic processes in complex ways, as described in Figure 
1.5.  In hepatocytes, XBP1 induces increased FA synthesis, while activation of 
ATF6α inhibits the induction of lipogenic genes by sterol regulatory element-binding 
protein (SREBP), however, mouse models lacking hepatic ATF6α showed increased 
steatosis regardless of the reduced levels of lipogenesis, indicating that more 
complex mechanisms were involved. ATF6α also has an inhibitory effect on 
gluconeogenesis, modulating the activity of the key transcriptional regulator cAMP-
response element binding protein (CREB). [32]  Also interestingly, liver samples 
from patients with non-alcoholic fatty liver disease have demonstrated elevated BiP 
expression and eIF2α phosphorylation.  Genetic modulation studies on the pathways 
involving eIF2α phosphorylation, IRE1α/XBP1, and ER protein translocation have 
linked ER stress and hepatocyte steatosis. [30]  Also, CHOP has been implicated in 
hepatocyte death as a mediator of decreased gene expression under severe ER stress 
[32]  
Several damaging agents that disrupt ER homeostasis, such as drugs, alcohol, lipids, 
and HBV and HCV have been shown to cause ER dysfunction through mediators 
such as ROS that cause oxidative stress, altered membrane lipid composition, and 
Figure 1.5:  Metabolic causes and consequences of ER stress and the UPR.  Hotamisligil, 2010  [32] 
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formation of protein aggregates, which can either be resolved or have more serious 
consequences such as inflammation, steatosis, and apoptosis of hepatocytes [30]. 
1.5.4 ER Stress, Epithelial to Mesenchymal Transition and Src Kinase 
It is also important to note that sustained ER stress and EMT appear to be closely 
related.  Recent studies on thyroid and alveolar epithelial cells have demonstrated 
that induction of ER stress by chemical inducers such as thapsigargin and 
tunicamycin resulted in epithelial to mesenchymal transition as demonstrated by loss 
of epithelial markers such as E-cadherin, and increase of mesenchymal markers such 
as α–smooth muscle actin (α-SMA), as well as morphological changes.  Both studies 
also utilized the PP2 inhibitor of Src-family kinases to demonstrate that the induction 
of dedifferentiation and EMT by ER stress was mediated by the Src pathway. [33] 
[34]  Src is a non-receptor proto-oncogene tyrosine protein kinase that is hyperactive 
in many cancers and is a drug target for tyrosine kinase inhibitors such as dasatinib.     
                               
1.6 FAM134B in Literature  
A review article published in EMBO Reports in 2010, titled “Further assembly 
required: construction and dynamics of the endoplasmic reticulum network” draws 
attention to the family with sequence similarity 134 (FAM134) family of proteins 
FAM134A, FAM134B and FAM134C, and points out that these proteins may 
constitute a new family of organelle-shaping proteins since each of the FAM134 
proteins have a pair of long hydrophobic segments similar to those found in 
reticulons and DP1/REEPs/Yop1. [35]  Reticulons are a class of membrane proteins 
shaping the tubular endoplasmic reticulum, primarily functioning in promoting 
membrane curvature. Reticulons interact with DP1/Yop1p, another tubular ER 
membrane protein, and their deficiency disrupts tubular ER. [36] 
A 2009 publication in Nature Genetics by Kurth et al. established that loss-of-
function mutations in FAM134B cause hereditary sensory and autonomic neuropathy 
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type II (HSANII), which involves severe mutilations due to diminished sensory 
perception and compromised regulation of involuntary functions of the body.  The 
FAM134B protein was shown to co-localize with the cis-Golgi protein giantin, and 
was therefore defined as a Golgi protein.  Using primary dorsal root ganglion 
neurons, it was revealed that knockdown of FAM134B results in a ~40% reduction 
in the size of the cis-Golgi compartment as well as apoptosis.  Analyses on multiple 
adult murine tissues showed that FAM134B was most highly expressed in the testis, 
followed by the dorsal root ganglion, while the liver had much lower expression 
levels.  [37] 
In 2007, Tang et al. published a study entitled “Oncogenic properties of a novel gene 
JK-1 located in chromosome 5p and its overexpression in human esophageal 
squamous cell carcinoma.”  JK-1 is an alias for FAM134B isoform 2, and this study 
established that elevated levels of JK-1 is associated with esophageal squamous cell 
carcinoma (ESCC) and can transform normal cells.  They observed that 30% (9/30) 
of ESCC tumors , and 69% (9/13) of ESCC cell lines had elevated levels of JK-1.  
They also demonstrated that overexpression of JK-1 promoted anchorage dependent 
and anchorage independent proliferation of benign NIH3T3 and HEK293 cells.  
Moreover, subcutaneous injections of NIH3T3 cells overexpressing JK-1 formed 
sarcomas in all three mice.  [38] 
Another interesting publication from 2011 assembled gene expression data from 
pluripotent stem cells and non-pluripotent cells of the mouse, and identified 
FAM134B as a biomarker of pluripotent stem cells in mice, and suggested that 
FAM134B may constitute a missing link between pluripotency and some 
unidentified surface markers processed by the Golgi apparatus. However, it is not 
clear from this paper whether FAM134B is overexpressed or underexpressed in 
pluripotent cells [39]   
FAM13B initially caught attention in our laboratory as a possible senescence-
associated gene, as its levels were elevated in senescent Huh7 clones compared to 
parental and immortal Huh7 clones.  Further studies implicated that FAM134B is not 
a cause but a result of senescence.  It was also identified to co-localize with the ER 
protein Calnexin.  FAM134B protein levels were also shown to be elevated in the 
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more mesenchymal-like, poorly-differentiated HCC cell lines compared to the more 
epithelial-like, well-differentiated ones, and we hypothesized that this could be 
associated with the elevated ER stress status of the more mesenchymal-like cell lines. 
[40][41] (Nilgün Taşdemir, Mustafa Yılmaz and Mehmet Öztürk, unpublished data)   
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2. OBJECTIVES AND RATIONALE 
Hepatocellular carcinoma constitutes 80% of liver cancers, which is the cancer type 
with the second poorest survival rates worldwide [3].  Risk factors for hepatocellular 
carcinoma include alcohol consumption and HBV or HCV infections, in addition to 
obesity, non-alcoholic fatty liver disease and diabetes, all of which appear to have 
devastating impacts on the endoplasmic reticulum and the cell, as described in the 
introductory section.  
FAM134B initially caught attention in our lab in comparative analyses, having 
elevated levels in senescent Huh7 clones compared to parental and immortal Huh7 
clones.   Further analyses showed that it may be localized on the ER, and that its 
levels are elevated in the more mesenchymal-like HCC cell lines, which also have 
elevated ER stress status. [40] 
An EMBO report published in 2010 drew attention to the FAM134B protein as a 
possible organelle shaping, reticulon-like protein of unknown function that is yet to 
be placed in the ER network [35].  And a 2009 publication in Nature identified 
FAM134B as a cis-Golgi protein for which loss-off function mutations cause 
neuropathy [37]. 
This research aims to identify the function of the FAM134B protein, with special 
focus on its role in hepatocellular carcinoma. 
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3. MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 General Laboratory Reagents and Kits 
General laboratory reagents, chemicals and kits utilized during the course of this 
thesis work were all laboratory-grade commercial products purchased from major 
companies. Tunicamycin, ready-made Bradford reagent, Bovine Serum Albumin 
(BSA), haematoxylene dye, agarose, ethanol and methanol were bought from Sigma-
Aldrich (St. Louis, MO, USA). Sulforhodamine B (SRB) dye was in powder form 
and also obtained from Sigma-Aldrich (St. Louis, MO, USA).  Thapsigargin was 
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). TGF-β1 was 
purchased from R&D Systems (Minneapolis, USA). Nucleospin RNA II total RNA 
isolation kit was purchased from Macherey-Nagel (Duren, Germany). TRIsure RNA 
isolation reagent used for tissues was purchased from Bioline (Taunton, USA).  
Ponceau dye and cell culture grade dimethyl sulfoxide (DMSO) were obtained from 
Applied Biochemia (Darmstadt, Germany). ECL prime detection reagent and Nitro-
cellulose western blot membranes were purchased from Amersham GE Lifesciences 
(Pittsburgh, PA, USA).  For immunoperoxidase staining, the DAKO EnVision+ 
system was used, which included blocking solution and secondary antibody mix 
(Glostrup, Denmark).  
3.1.2 Cell Culture Solutions and Materials  
Dulbecco’s modified Eagle’s medium (DMEM) and Roswell Park Memorial Institute 
(RPMI) cell culture mediums, fetal bovine serum (FBS), penicillin/streptomycin 
antibiotics, L-glutamine and trypsin-EDTA were purchased from GIBCO 
(Invitrogen, Carlsbad, CA, USA).   The plastic items used in cell culture such as cell 
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culture plates, flasks and serological pipettes were obtained from Corning Life 
Sciences Inc. (USA).  
3.1.3 Electrophoresis Apparatus 
The SDS-PAGE gel electrophoresis equipment, including the tanks, the gel 
preparation glasses, power supplies and other plastic materials were purchased from 
BIO-RAD Laboratories (CA, USA).  Agarose gel electrophoresis apparatus and 
NanoDrop spectrophotometry apparatus to measure nucleic acid concentration were 
obtained from Thermo Scientific (Wilmington, USA).  Protein concentration was 
determined using Bradford reagent which was measured using the spectrophotometer 
Beckman Du640 from Beckman Instruments Inc. (CA, USA).  
3.1.4 cDNA Synthesis and Polymerase Chain Reaction Reagents 
All reagents required for cDNA synthesis from total mRNA and semi-quantitative 
polymerase chain reaction (PCR) were obtained from Fermentas (MBI Fermentas, 
Germany), including RevertAid First strand cDNA synthesis kit, Taq DNA 
polymerase, 10X Taq DNA polymerase Buffer (+(NH4)2SO4,–MgCl2), 2mM dNTPs, 
25mM MgCl2 and DNA molecular weight ladders. 
3.1.5 Primers 
Primers were ordered from Sentromer (Istanbul, Turkey). 
Primer Sequence Tm 
mmFAM134B isoform 1 For. AGC TCC TGA GCT GGA AGA GG 61 
mmFAM134B isoform 1 Rev. TCA TGA CGG AAA TGA GGT GA 55 
mmFAM134B isoform 2 For. GCT GTG GAC CAG GCA GAA G 61 
mmFAM134B isoform 2 Rev. AAA TTC ATC CAT GAT TCT GCA A 53 
mmXBP-1spl.unspl. For.  AGT TAA GAA CAC GCT TGG GAA T 57 
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mmXBP-1 spl.unspl. Rev.  AAG ATG TTC TGG GGA GGT GAC 60 
hFAM134B isoform 1 For. CAAGAGGTGCACAGTTGTGGAGAA 58 
hFAM134B isoform 1 Rev. GCAACCGTGAGGCTAATCTTAGGA 58 
hFAM134B isoform 2 For. 
CTCGAGAAGCTTATGCCTGAAGGTGAA
GACTT 
58 
hFAM134B isoform 2 Rev. GCAACCGTGAGGCTAATCTTAGGA 58 
hXBP-1 For.  TTACGAGAGAAAACTCATGGCC 58 
hXBP-1 Rev.  GGGTCCAAGTTGTCCAGAATGC 62 
hGAPDH For.  GGCTGAGAACGGGAAGCTTGTCAT 60 
hGAPDH Rev.  CAGCCTTCTCCATGGTGGTGAAGA 60 
hVimentin For. CGTCACCTTCGTGAATACCA 60 
hVimentin Rev. CCAGAGGGAGTGAATCCAGA 60 
Table ‎3-1:  Primer sequences and Tm values. 
3.1.6 Antibodies 
Antibody Company and Catalog Number Dilution 
FAM134B Sigma, HPA026906 1:2500 
Phospho-eIF2α Invitrogen, 44728G   1:1000 
Vimentin Dako, M7020 1:500 
Calnexin Sigma, C4731 1:5000 
α-tubulin Calbiochem, CP06 1:4000 
actin Santa Cruz, sc-1616-R 1:5000 
anti-mouse-HRP Sigma, A0168 1:5000 
anti-rabbit-HRP Sigma, 6154 1:5000 
Table ‎3-2: Antibodies, source companies and dilutions used. 
24 
 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General solutions  
10X Phosphate Buffered 
Saline (PBS) 
80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 in 1 
liter ddH2O 
50X Tris Acetate EDTA 
(TAE) 
242 g Tris base, 57.1 ml glacial acetic acid, 18.6 EDTA 
in 1 liter ddH20 
6X DNA Loading Dye  10mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 
0.03% xylene cyanol, 60% glycerol, 60mM EDTA 
(0.5M pH8.0) 
Ethidium Bromide  10 mg/ml dissolved in ddH2O (stock) 
1:10.000 working dilution (1µl per 10ml of gel) 
3.2.2 Tissue culture solutions  
Complete Medium  500ml DMEM/RPMI medium, 10% filtered and 
inactivated fetal bovine serum, 1% penicillin / 
streptomycin, 1% non-essential amino acids, 1% L-
glutamine.  Stored at 4  C  
Freezing Medium 20% FBS and 7% DMSO added to complete medium 
10X Phosphate buffered 
saline (PBS) 
80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 in 1 
liter ddH2O,  working dilution: 1X, autoclaved and 
stored at 4  C 
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3.2.3 RIPA Lysis Buffer for Protein Extraction  
The RIPA lysis buffer for protein extraction was prepared in advance excluding the 
protease inhibitor and NaF and NaVO4 which serve as phosphatase inhibitors, and 
stored in 4  C as stock.  Protease inhibitor and the phosphatase inhibitors were added 
fresh before use, and this solution could only be stored up to 3 months at -20  C. 
 Stock 
Concentration 
Final 
Concentration 
For 1ml For      
50ml stock 
ddH2O   730µl 36.5ml 
NaCl 2M 150mM 75 µl 3.750ml 
NP-40/TritonX  1% 10 µl 500 µl 
Sodium DOC 10% 0.5% 50 µl 2.500ml 
SDS 10% 0.1% 10 µl 500 µl 
Tris-HCl pH8 2M 50mM 25 µl 1.250ml 
Protease 
Inhibitor 
25X 1X 40 µl * added fresh 
NaF 1M 50mM 50 µl * added fresh 
NaVO4 100mM 1mM 10 µl * added fresh 
Table ‎3-3:  RIPA lysis buffer ingredients and recipe. 
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3.2.4 Sodium Deodecyl Sulphate–Polyacrylamide Gel Electrophoresis (SDS-
PAGE) Gels and Solutions for Western Blotting 
10% Running Gel                
(7mls recipe for 1 gel) 
2.66ml ddH2O, 2.38ml 30% Acrylamide Mix, 1.82ml 1.5M 
Tris-HCl pH8.8, 70 µl 10% SDS, 70µl 10% Ammonium 
Per Sulfate, 2.8µl TEMED  
5% Stacking Gel              
(3mls recipe for 1 gel) 
2.1ml ddH2O, 500µl 30% Acrylamide Mix, 380µl 1M Tris-
HCl pH6.8, 30µl 10% SDS, 30µl 10% Ammonium Per 
Sulfate, 3µl TEMED  
10X SDS Running 
buffer 
 
144g glycine, 30g Tris were dissolved in dH2O, 50ml 10% 
SDS was added, and the volume was completed to 1 L.   
Working solution is 1X. 
 
10X Transfer buffer  72g glycine, 58g Tris were dissolved in dH2O, 2ml 10% 
SDS was added, and the volume was completed to 1 L.   
Working solution is 1X containing 15-20% EtOH  
Protein Loading Dye 5% 14.3M β-mercaptoethanol was added to protein loading 
dye before use 
10X Tris buffered 
saline (TBS) 
12.19g trisma base and 87.76g NaCl were dissolved in 1 L 
of ddH2O, and pH is adjusted to 8.  
TBS-T (0.2%) 10X TBS diluted to 1X working solution, and 2:1000 
Tween added 
Coomassie brilliant 
blue solution 
100mg coomassie brilliant blue G-250, 50ml 95% ethanol, 
100ml 85% phosphoric acid. Filtered using whatman paper 
Ponceau solution 0.1% (w/v) Ponceau S and 5% (v/v) acetic acid in ddH2O 
Blocking solution 5% (w/v) non-fat dry milk or 5% (w/v) Bovine Serum 
Albumin (BSA) dissolved in TBS-T 
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3.2.5 Immunoperoxidase staining solutions  
Fixation 1:1 Acetone:Methanol 
Washing solution PBS-T; 0.2%  Tween 20 in 1X PBS 
Antibody dissolved in  2% FBS in 0.2% PBS-T 
3.2.6 Sulforhodamine B (SRB) staining solutions  
10% TCA 10% (wt/vol) trichloroacetic acid in ddH2O 
10X (4%) SRB Stock 4g SRB powder dissolved in 100ml 1% acetic acid, stored 
at room temperature, working dilution is 1X 
Tris Base Solution  10mM Tris base solution was prepared with no pH 
adjustment 
1% acetic acid 1% (vol/vol) acetic acid in ddH2O 
 
 
3.3 METHODS 
3.3.1 Mouse Experiments 
3.3.1.1 Tunicamycin Treatment of the Mice 
14 C57 black 6 (C57BL/6) laboratory mice of around 20g of body weight, fed with 
normal diets were used for these experiments. The 14 mice were separated into 2 
groups of 7; one was the sucrose control group, the other was the tunicamycin 
treatment group.  The tunicamycin treated group was injected with 1ug/g body 
weight of tunicamycin; the tunicamycin solution was prepared at a concentration of 
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100ug/ml, therefore, a mouse of 20grams body weight received an injection of 200ul.  
The tunicamycin was dissolved in a 150mM sucrose solution which was prepared in 
physiological saline. The sucrose control group was injected with 150mM sucrose 
solution at a volume of 10ul/g body weight, again equaling a 200µl injection for a 
20g mouse.  The mice were maintained for 8 hours under normal conditions during 
the course of the 8 hours of tunicamycin treatment. 
3.3.1.2 Collection of Liver Tissue from Mice 
The mice were sacrificed and liver tissues were collected.  Each liver sample was 
divided into 3 sections; one for RNA isolation, one for protein isolation, and one for 
immunohistochemistry (IHC).  The sections reserved for RNA and protein isolation 
were immediately frozen in liquid nitrogen and stored at -80  C.  The sections 
reserved for IHC were fixed in 4% formaldehyde for one day and then paraffinated 
and stained with Hematoxylin and eosin method by the Animal Facility technicians. 
3.3.1.3 RNA Isolation from Mice Liver Tissues 
The TRIzol or TRIsure method was used to isolate RNA from tissues; all steps were 
performed on ice in the fume hood.  A section of 50-100mg of each tissue was put in 
a round bottom tube containing 1.5mls of TRIsure, the mixture was homogenized 
using a sterilized homogenizer, which was cleaned with ddH2O and sterilized with 
ethanol between each sample.  The contents were pipeted to a 2ml eppendorf, and 
300µl chloroform was added, and they were mixed vigorously by shaking up and 
down for 15 seconds. After 3 minutes at room temperature, they were centrifuged at 
15000rpm for 15 minutes, at 4  C.  The clear top layer of supernatant was taken into a 
new eppendorf without touching the white interphase that contained cell waste. 
750µl isopropanol was added and mixed slowly.  After 10 minutes at room 
temperature, the mix was centrifuged at 14000rpm for 10 minutes at 4  C.  The 
isopropanol was removed carefully, keeping the RNA pellet.  The RNA pellet was 
washed twice with ethanol, for 8 minutes at 8000rpm at 4  C.  The pellet was then 
dried under the fume hood and dissolved in RNAse DNAse free water, and stored at 
-80  C. 
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3.3.1.4 Protein Isolation from Mice Liver Tissues 
The following steps were performed on ice. A 50-100ug section of each tissue was 
homogenized in 500µl RIPA buffer, then kept on ice and vortexed every 5 minutes 
for 30 seconds.  The samples were then sonicated and centrifuged at 11000rpm for 
30 minutes, at 4  C. The supernatants were taken into new eppendorfs, and the 
centrifugation step was repeated two more times in order to get rid of the lipids that 
stick to the eppendorf during centrifugation.  The samples were stored at -80  C. 
3.3.2 Tissue culture methods 
3.3.2.1 Culturing of HCC Cell Lines 
Huh-7, PLC, Hep40 and Hep3B cell lines were cultured in complete DMEM medium 
while Snu387, Snu398, Snu449, and Snu475 were cultured in complete RPMI 
medium.  Complete mediums contained 10% inactivated and filtered fetal bovine 
serum, 1% penicillin/streptomycin antibiotics, 1% L-glutamine, and 1% non-
essential amino acids. The cells were maintained in incubators at 37°C with filtered 
air circulation containing 5% carbon dioxide. Cells were passaged before reaching 
full confluency in order to prevent cell cycle arrests.  All liquids such as mediums 
and PBS that come in contact with the cells were heated to 37  C in the water bath 
before use, and all equipment and solutions utilized were sterile. 
3.3.2.2 Cell Passaging 
In order to passage the cells, the medium was aspirated and the cells were washed 
once with PBS. The cells were then trypsinized using 500-2000µl of trypsin 
depending on size of the plate or flask, and incubated at 37  C for 1-2 minutes to 
activate the trypsin and detach the cells.  The cells were collected from the plates 
using complete medium, and pipeted well to dissociate any clumps.  The required 
amount of cells was transferred to a new dish in fresh medium, the amount of which 
is determined according to the dish or flask used. 
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3.3.2.3 Cell Thawing 
In order to start a new cell culture from a cryopreserved stock in liquid nitrogen or -
80  C freezer, the vial was first only briefly kept on ice or at -20  C.  It was then 
quickly thawed in the 37  C water bath for a few minutes, and transferred to a 15ml 
falcon which contained 10mls of medium warmed to 37  C, and mixed well.  The 
falcon was then centrifuged at 1500 rpm for 4 minutes and the medium was aspirated 
to remove any DMSO from cryopreservation. The dish or flask size to be used was 
determined according to the size of the cell pellet.  The pellet was dissolved in new 
complete medium and transferred to a new dish or flask, and was dispersed well by 
moving the plate side to side and back and forth.  The cells were then incubated at 
37  C and 5% carbon dioxide, and checked regularly to change the medium or be 
passaged before reaching confluency.  
3.3.2.4 Cell Cryopreservation  
Cells were cryopreserved when they reach 70-80% confluency since cells that are too 
confluent can go into growth arrest.  Cells were washed with PBS, trypsinized, 
collected into falcons and centrifuged at 1500 rpm for 4 minutes, and medium was 
aspirated.  The cell pellet was then resuspended in freezing medium with 20% FBS 
and 7% DMSO and pipeted well to ensure there were no clumps.  The number of 
vials to preserve depended on pellet size, and each vial was prepared to contain 
around enough cells to fill a 10mm dish, resuspended in 1.5-2mls of freezing 
medium. The vials were initially cooled for 1hour at -20°C and then transferred to -
80°C and liquid nitrogen for preservation.  
3.3.2.5 Cell Treatments 
The cells were plated in the suiting plates, dishes or flasks in specific numbers that 
aimed the control cells to reach a confluency of 80-90% by the end of the total 
treatment period.  24 hours after seeding, the mediums were changed to contain the 
desired concentration of the chemical in complete medium, prepared fresh.  Mediums 
used for the control samples contained the solvent of the drug, such as DMSO.  
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3.3.3 mRNA Expression Analyses  
3.3.3.1 Total RNA Extraction from Cells 
The cells were collected by trypsinization, and after the first centrifuge and removing 
the medium, the pellet was washed a second time with cold PBS and centrifugation.  
The pellet could be stored at -80°C.  Total RNA isolation was carried out using the 
protocol provided with the NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren, 
Germany).  
3.3.3.2 cDNA synthesis (Reverse Transcription) 
RNA concentrations were determined using NanoDrop and equal amount of total 
RNA from each sample was used, which was 2-4ug.  The Fermentas RevertAid 
cDNA synthesis Kit (MBI Fermentas, Germany) was utilized to carry out cDNA 
synthesis in a total volume of 20ul, as described by the protocol provided with the 
kit, using the thermocycler machine. The initial step of incubating the RNAs only 
with Oligo(dT) primers ensured that only the mRNAs with PolyA tails can be reverse 
transcribed.  Then dNTPs, Ribonuclease inhibitor, reaction buffer, and finally, 
RevertAid MuLV Reverse Transcriptase were added to complete the reverse 
transcription.  Reverse transcriptase negative controls for each sample were also 
prepared to ensure there was no genomic DNA contamination, which could be 
detected in the PCR products as a band of a different size due to introns. 
3.3.3.3 Primer Design for Semi-Quantitative RT-PCR   
Primers were designed to be on different exons so that a PCR product from genomic 
DNA would have a different size since it contained an intron.  Also, specifity for the 
desired mRNA was double-checked in BLAST, and primers yielding homo- or 
hetero-dimers were eliminated using predictions on the online IDT Oligo Analyzer 
tool. The forward and reverse primer pairs were also adjusted to have similar melting 
temperatures, and low GC contents. 
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3.3.3.4 Polymerase Chain Reaction 
GAPDH was always used as a loading control.  Optimizations on melting 
temperature were made using Gradient PCR when needed.  The total volumes of the 
reactions were 25ul, and 10µl reactions were used for optimizations to spare cDNA.   
The core reaction was;  
Initialization 5 minutes at 95°C  
Denaturation 30 seconds at 95°C  
Annealing 30 seconds at 58-60°C  20-30-32 cycles 
Elongation 30 seconds at 72°C  
Final Extention 10 minutes at 72°C  
Final Hold 4°C  
 
3.3.3.5 Agarose Gel Electrophoresis 
The gel was prepared to contain 2-3% agarose and ethidium bromide in 1X TAE. 
The separation of the unspliced and spliced XBP bands could best be visualized with 
a 3% gel. PCR products were mixed with 6X loading dye and loaded very carefully 
to ensure correct comparison.  The gels were run at 100-130V voltage to get sharp 
bands, with 50bp ladders, and visualized under UV light.  
3.3.4 Protein Level Analyses  
3.3.4.1 Total Protein Extraction from Cultured Cells 
The cells were collected via trypsinization or scraping, and washed with cold PBS.  
All PBS was removed with a second centrifugation step.  The pellets were 
resuspended in 30-25µl of RIPA Lysis Buffer depending on pellet size.  They were 
kept on ice and vortexed every 5 minutes for 30 minutes.  The samples were then 
sonicated and boiled for 3 minutes to separate DNA.  The samples were then 
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centrifuged at 15000rpm for 1 hour at 4°C.  Supernatants were collected to new 
eppendorfs and protein concentrations were determined using the Bradford method, 
often in triplicates of different concentrations to ensure equal loading. The 
absorbances were measured at 595nm in the spectrophotometer, and the 
concentrations were calculated from the absorbance values using the formula of the 
reference BSA graph obtained by absorbance values of BSA solutions of known 
concentrations. 
3.3.4.2 Western blotting  
After determining the protein concentration of each sample, the volume required for 
20-30ug of protein from each sample was calculated, and an equal total protein 
amount among all samples was ensured.  Samples were prepared for loading with the 
addition of a 5X SDS loading dye containing 5% β-mercaptoethanol as a denaturing 
agent and water to complete to same total amount of around 25ul.  Before loading, 
these mixtures were boiled at 100°C for 10 minutes for denaturing.       
The gels, running buffers and transfer buffers were prepared as described in the 
recipes in the materials section.  During running and transfer, the buffers were kept 
cool by placing a cooler into the tank.  Running was performed at a fixed ampere, 
which was about 20mA per gel, and lasted 1-2 hours.  The sponges, whatman papers 
and nitrocellulose membranes were wetted in transfer buffer prior to setting up the 
wet transfer.  The transfer was performed at 100V for 60 minutes. After visualization 
of the total protein with Ponceau dye to ensure equal loading, the membranes were 
shaken slowly at room temperature in blocking solution for 1 hour.  Primary 
antibody incubations were done at 4°C overnight on a slow shaker, secondary 
antibody incubations were done for 40-60 minutes at room temperature on slow 
shaker, and washes were done on vigorous shaking with TBS-T for 5-15-5 minutes.  
The bands were visualized using ECL prime western blot detection kit (Amersham, 
Buckinghamshire, UK) prepared 1:1 and developed for 5 minutes.  Exposure times to 
X-ray film varied between 10 seconds to 10 minutes, depending on antibody 
strengths. 
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3.3.4.3 Immunoperoxidase Staining 
Before plating the cells on 6-well plates, an autoclave-sterilized coverslip was placed 
at the bottom of each well.  After plating the cells in equal amounts, the plates were 
shaken side to side and back and forth to ensure equal dispersion. The cells were 
grown 24 hours and then washed slowly with cold PBS.  They were then fixed for 5 
minutes with ice-cold 1:1 methanol:acetone mixture, which also allowed 
permeabilization of the membranes.  
The cells were blocked with Lab Vision Blocking Solution provided with the DAKO 
kit, or 5% BSA in PBS for 10 minutes.  Primary antibody was prepared in 3% BSA 
in PBS, and incubated 2 hours at room temperature, ensuring the slides cannot go 
dry.  50µl of primary antibody mixture was enough for one coverslip. The slides 
were washed 3 times for 3 minutes in PBS-T and excess was dried. As a secondary 
antibody, the slides were incubated with Lab Vision Biotinylated Goat Anti-
Polyvalent for 10 minutes, lid closed. The slides were washed 3 times for 3 minutes 
in PBS-T and excess was dried and then incubated with Lab Vision Streptavidin 
Peroxidase for 10 min, lid closed.  The slides were washed 3 times and dried as 
before. DAKO DAB was prepared 1 drop in 1000ul, vortexed, and kept in dark.  
Each sample was incubated with DAB for 5 minutes, and washed with plenty of 
ddH2O.  Hematoxylene was filtered, vortexed and poured in a tissue staining jar, and 
slides were kept in Hematoxylene for 30 seconds, and then washed thoroughly under 
running tap water.  Excess water was dried off and coverslips were mounted onto 
microscopic slides using DAKO Fluorescent Mounting Medium and photographed.  
3.3.5 Stable Knockdown with shRNA 
The stable knockdowns of FAM134B expression in Snu449 cells were performed by 
previous lab members (P. Telkoparan, H. Alotaibi, N. Tasdemir, of M. Ozturk Lab, 
personal communication) using pGIPZ plasmids which conferred puromycin 
resistance to the cells.  Puromycin resistance was utilized to select and proliferate 
single colonies that expressed the plasmid carrying the shRNA construct for 
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FAM134B.  Stable cell lines were maintained in puromycin-containing medium, and 
knockdowns were confirmed using western blot and reverse transcription PCR. 
3.3.6 Wound Healing / Scratch Assay 
The cells were plated in complete medium on 6-well plates in numbers enough to 
reach 100% confluency after 24hours, which was about 400.000 for the stable 
Snu449 cell lines.  After 24 hours, when the cells have become confluent, the wells 
were washed gently with PBS, and scratches were introduced using a micropipette 
tip.  Wells were washed twice more with PBS, and new medium with 0.05% FBS 
was put on the wells, to prevent cell division. To observe migratory behavior, the 
cells were photographed at the same region at 0 hours, 24 hours and 48 hours. 
3.3.7 Sulforhodamine B (SRB) Colorimetric Assay  
A 96well plate was prepared for an SRB assay by labeling and filling the outer wells 
with 200µl PBS to prevent evaporation of samples. The cells were counted and 
prepared in the right concentration in order to be plated at equal numbers (4000 for 
Snu449 cells) in 100µl of medium. After 24 hours, the drugs were prepared in 
increasing concentrations, as 2X in 100ul; when added onto the previous 100µl 
medium on the cells, the concentration becomes the desired 1X concentration.  The 
samples were all prepared in triplicates.  
After 72 hours of incubation with the drugs, the cells were fixed with 10% TCA for 
60 minutes at 4°C, and then washed with dH2O and air-dried either under the fume 
hood for 1 hour or at benchtop overnight.  Then they are stained with 0.4% SRB in 
1% acetic acid, for 10 minutes in dark, and washed 3-5 times with 1% acetic acid to 
get rid of excess, unbound dye.  After air drying, 10mM Tris base solution is added 
onto the wells to dissolve the protein-bound dye, from which an OD reading is 
obtained at the plate reader at 405nm.   
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4. RESULTS 
4.1 FAM134B in Humans & Mouse 
This section provides introductory gene and protein information on FAM134B in 
Homo sapiens and Mus musculus, obtained from the databases of the NCBI (National 
Center for Biotechnology Information) and Ensembl. 
4.1.1 FAM134B Gene & Transcript Information 
FAM134B is a protein-coding gene. The gene name FAM134B stands for “Family 
with sequence similarity 134, member B.”  Other aliases for the human gene include 
JK1, FLJ20152, FLJ22155, and FLJ22179, and its NCBI GeneID is 54463.  The 
human FAM134B gene is located of chromosome 5, while mouse FAM134B gene is 
located on chromosome 15.  
The human FAM134B gene encodes two transcripts produced by alternative splicing. 
Transcript variant 1 (NM_001034850, gi|77917616) has a linear full-length mRNA 
of 3259 bps (basepairs), and the translated region is 1494 bps.  Transcript variant 2 
(NM_019000, gi|77917615) has an mRNA length of 3108 bps, and the translated 
region is 998 bps. 6 exons at the 3’ ends of the two transcripts are identical, and 
transcript 1 has 3 additional unique exons while transcript 2 has 1 additional unique 
exon at the 5’ ends; 
 
The mouse FAM134B gene, on the other hand, encodes 6 mRNA transcripts, also 
produced by alternative splicing of exons. 
Figure 4.1:  Genomic region and transcripts of FAM134B. 
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4.1.2 Protein Information on FAM134B 
The two transcripts of human FAM134B code for two different FAM134B protein 
isoforms.  Isoform 1 (NP_001030022) is 497 amino acids long, making up a protein 
of about 55kDa (kilo daltons) in mass, while isoform 2 (NP_061873) is 356 amino 
acids long, making up a protein of about 39 kDa.  In western blots, both isoforms 
appear to have a higher mass than predicted, possibly due to post-translational 
modifications.   
4.1.2.1 Domains, Motifs and Possible Sites of Post-Translational Modifications 
on the FAM134B Protein 
Human FAM134B protein isoform 1 has two transmembrane domains at the N-
terminal end, and one coiled coil domain at the C-terminal end, while isoform 2 has 1 
transmembrane domain at the N-terminal end and one coiled-coil domain at the C-
terminal end.  
A review titled “Further assembly required: construction and dynamics of the 
endoplasmic reticulum network” published in EMBO Reports in 2010 draws 
attention to the fact that the FAM134 family proteins each have a pair of long 
hydrophobic segments similar to those found in reticulons and DP1/REEPs/Yop1, 
and that the members of the FAM134 family proteins may therefore be a new family 
of organelle-shaping proteins [35].  
The SWISSPROT MotifScan tool also predicts that the FAM134B proteins may have 
sites for phosphorylation, N-glycosylation, and N-myristoylation.  Possible 
phosphorylating candidates will be discussed later in detail. 
4.1.3 Initial Findings on FAM134B  
The FAM134B gene initially caught attention in our lab as a possible replicative 
senescence associated gene; increased FAM134B expression was detected in the 
replicative senescent Huh7 clones in comparison with the immortal counterparts 
[41].  Previous findings in our lab also suggested that the more poorly-differentiated 
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HCC cell lines had higher levels of FAM134B protein compared to the more well-
differentiated HCC cell lines, and that this may be associated with the elevated ER 
stress levels of the poorly-differentiated cell lines [40]. 
4.2 FAM134B in Endoplasmic Reticulum Stress in vivo  
Since previous findings by our group implicated that elevated levels of FAM134B 
protein may be associated with elevated levels of ER stress in HCC cell lines [40], 
we wished to further investigate this possibility in vivo as well.  
4.2.1 Tunicamycin-induced ER stress causes a steatosis-like appearance in 
mice liver tissues 
Tunicamycin is an antibiotic mixture that is commonly used for the induction of ER 
stress.  Tunicamycin prevents the N-glycosylation of proteins in the ER, causing the 
accumulation of proteins in the ER, leading to ER stress.  
Treatment of mice for 8 hours with 1ug/g body weight tunicamycin injected 
intraperitoneally lead to the appearance of a steatosis-like appearance in the liver 
tissues as seen in Figure 4.2.  The liver tissues were stained with the Haematoxylene 
& Eosin staining technique which excludes lipids, causing the appearance of white, 
unstained regions. As seen in Figure 4.1, the tunicamycin treated mice liver tissues 
displayed lipid accumulation in the cytoplasms of the hepatocyte cells.  
Figure 4.2:  8 hours of 1ug/g body weight tunicamycin treatment causes lipid accumulation 
and a steatosis-like morphology in mice liver tissue. 
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4.2.2 FAM134B expression is not affected in tunicamycin-induced ER stress in 
mice liver tissues 
As seen in the Reverse-Transcription PCR results provided in Figure 4.3, 8 hours of 
induction of ER stress by tunicamycin treatment did not affect the mRNA expression 
levels of FAM134B, despite the visible splicing of XBP-1, which is an indicator of 
ER stress downstream of IRE1 in the unfolded protein response, as described 
previously.  
4.2.3 FAM134B protein level is not affected in tunicamycin-induced ER stress 
in mice liver tissues 
As demonstrated in the western blotting results provided in Figure 4.4, tunicamycin 
treatment does not affect the protein levels of FAM134B in mice liver tissues, even 
though there is a significant elevation in the levels of phosophorylated eIF2α, which 
is an indicator of ER stress downstream of PERK in the unfolded protein response. 
Figure 4.4:  ER stress induction by 8 hours of 1ug/g body weight tunicamycin treatment does 
not affect the protein levels of FAM134B significantly in liver tissues of mice. Each number 
represents a different mouse; 7 mice were injected with sucrose, and 7 with tunicamycin. 
Figure 4.3:  ER stress induction by 8 hours of 1ug/g body weight tunicamycin treatment does 
not affect the levels of FAM134B mRNA expression in liver tissues of mice.  Each number 
represents a different mouse; 7 mice were injected with sucrose, and 7 with tunicamycin. 
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Figure 4.5:  Relative FAM134B mRNA levels from the CCLE database. 
Figure 4.6:  Basal FAM134B mRNA levels of selected HCC cell lines. 
4.3 FAM134B in vitro  
4.3.1 Basal Levels of FAM134B in HCC cell lines 
4.3.1.1 CCLE FAM134B Expression Data in HCC cell lines 
The Cancer Cell Line Encyclopedia (CCLE) of the Broad Institute was utilized to 
select HCC cell lines with low and high expression levels of FAM134B.  As seen in 
Figure 4.5, Hep3B, Huh7 and PLC cell lines have lower expression values, while 
Snu387, Snu398, Snu449 and Snu475 cell lines have higher expression values. 
 
 
 
 
 
 
 
 
4.3.1.2 Basal mRNA Expression levels of FAM134B in selected HCC cell lines 
Semi-quantitative RT-PCR was performed on selected HCC cell lines to determine 
their FAM134B mRNA levels. 
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4.3.1.3 Basal Protein levels of FAM134B in selected HCC cell lines 
Western blot was performed in order to determine the basal FAM134B protein levels 
in the selected cell lines. PLC, Huh7 and Hep3B cells, which are considered to be 
well-differentiated and more epithelial-like due to their cell morphology and 
vimentin expression levels [42], had very low FAM134B protein levels, while 
Snu387, Snu398, Snu475, and Snu449 cells, which are considered to be poorly-
differentiated and more mesenchymal-like, had much higher levels of FAM134B 
protein levels.  
 
 
 
 
 
 
 
 
Previous findings in our lab demonstrated that the overexpression of FAM134B does 
not induce Epithelial-to-Mesenchymal Transition (EMT) [40], therefore, it is likely 
that the elevated levels of FAM134B in the poorly differentiated cell lines is not a 
cause but a result of EMT, and this will be investigated further. 
4.3.1.4 Sub-cellular localization of FAM134B protein in Snu387 cells  
Immunoperoxidase staining of Snu387 cell lines was performed with the FAM134B 
antibody in order to observe the sub-cellular localization of the FAM134B protein. 
As can be observed in Figure 4.8, FAM134B demonstrates a perinuclear staining like 
that of Calnexin, which is indicative of localization on the Endoplasmic Reticulum. 
Figure 4.7:  Basal FAM134B protein levels were higher in the more poorly-differentiated HCC cell 
lines compared to the well-differentiated HCC cell lines selected.  The heavier band represents 
FAM134B isoform 1, while the lower band represents isoform 2.  
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4.3.2 FAM134B and ER stress  
4.3.2.1 ER stress does not significantly affect mRNA expression levels of 
FAM134B in selected HCC cell lines  
Tunicamycin, thapsigargin and dithiothreitol (DTT) are well-characterized ER stress 
inducers.  Thapsigargin inhibits the sarco-endoplasmic reticulum Ca
2+
 ATPases 
(SERCA); this causes the ER to be unable to pump calcium from the cytosol to the 
ER lumen [43].  DTT breaks disulfide bonds, which causes proteins to unfold. 
As seen in Figure 4.9, when ER stress was induced in Huh7, Snu387, Snu449 and 
Snu475 cell lines using these three ER stress inducers at different concentrations for 
1, 6 and 24 hours, there was no significant effect on the mRNA levels of FAM134B, 
even when there was clear splicing of XBP-1, which marks ER stress.  
 
Figure ‎4.8:  FAM134B demonstrates a perinuclear staining like that of Calnexin, which 
indicates localization on the Endoplasmic Reticulum. 
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Figure ‎4.9:  In Huh7, Snu387, Snu449 and Snu475 cell lines, FAM134B mRNA expression levels 
are not significantly affected by ER stress induction with Tunicamycin, Thapsigargin and DTT 
for 1, 6 and 24 hours. 
44 
 
4.3.3 Effect of 6 hours of ER stress induction on FAM134B protein levels in 
selected HCC cell lines 
Western blotting was performed in order to detect changes in FAM134B protein 
levels in response to 6 hours of 2µM thapsigargin, 10µg/ml tunicamycin and 5mM 
DTT treatment, and there was no significant change at the protein level either. 
 
The only exception was Snu449 cells, which demonstrated an increase in FAM134B 
protein in response to DTT treatment.  Interestingly, as can be seen in Figure 4.11, 
Snu449 cells under DTT treatment were the only ones to demonstrate a significant 
ratio of cell death.  
Figure 4.11 on the next page shows the cell morphologies and cell death patterns of 
the selected cell lines under 6 hours of different ER stress inducing treatments. 
Also of note, in the western blot images in Figure 4.10 and Figure 4.7, there is a 
second, less abundant band right on top of the smaller isoform of the FAM134B 
protein.  This may be indicative of a post-translational modification that has made a 
sub-group of FAM134B isoform 2 proteins slightly heavier than the rest, causing this 
band that is shifted. 
Figure 4.10:  6 hours of ER stress induction with tunicamycin, thapsigargin and DTT does not 
significantly affect FAM134B protein levels in selected cell lines, with the exception of DTT 
treatment in Snu449 cells. 
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Figure ‎4.11:  Cell morphology and cell death patterns under ER stress induction for 6 hours 
with different inducers.  Snu449 cells under 5mM of DTT treatment for 6 hours showed a 
significant ratio of cell death. 
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4.3.4 FAM134B and EMT  
4.3.4.1 Huh7, PLC and Hep40 cells display a more dispersed growth pattern 
upon 72 hours of TGF-β1 treatment 
TGF-β induces Epithelial-to-Mesenchymal Transition (EMT) by triggering the 
activation of the transcription factors Snail, ZEB and Twist, which regulate the 
upregulation of mesenchymal markers such as Vimentin and downregulation of 
epithelial markers such as E-cadherin [44]. 
In order to induce EMT in the more well-differentiated HCC cell lines Huh7, PLC 
and Hep40, cells were treated with 2ng/ml and 4ng/ml TGF-β1 for 72 hours.  As 
seen in Figure 4.12, the cells displayed a more dispersed morphology after this 
treatment. 
Figure 4.12:  The well-differentiated HCC cell lines Huh7, PLC and Hep40 assume a more 
mesenchymal-like morphology after 72 hours of treatment with TGF-β1. 
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4.3.4.2 Upon EMT induction, PLC cells display a dramatic increase in 
Vimentin, accompanied by an increase in FAM134B protein levels 
PLC cells were the cell line that exhibited the most apparent morphological changes 
upon induction of EMT with 72 hours of TGF-β1 treatment.  As demonstrated by the 
western blot and the graphs in Figure 4.13, the Vimentin levels of PLC cells 
increased dramatically, and this increase in Vimentin levels was accompanied by an 
elevation in FAM134B levels. 
Proteins such as actin, calnexin or tubulin which are normally used as loading 
controls could be affected by EMT induction by TGF-β1, therefore the Ponceau 
staining was taken into consideration when making sure of equal loading.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.13:  Western blot and graph of relative expression levels normalized to the 
Ponceau staining demonstrate a dramatic increase in Vimentin levels in PLC cells, which 
is accompanied by an increase in FAM134B levels. 
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4.3.5 FAM134B knockdown experiments in Snu449 cells 
4.3.5.1 Successful silencing of FAM134B with shRNA transfection 
Stable transfection of Snu449 cells with shRNA constructs against FAM134B 
mRNA was performed by previous group members (P. Telkoparan, H. Alotaibi, N. 
Taşdemir, of M. Öztürk Lab). Cells were maintained with puromycin in culture to 
ensure persistence of knockdown cells, and western blots were performed to assess 
protein levels of FAM134B in the knockdowns. As seen in Figure 4.14,  FAM134B 
protein levels were reduced to about 40% in two clones, 59-11 and 59-12, while the 
scrambled control RNA appeared to cause overexpression of FAM134B protein. 
 
These results were confirmed also at the mRNA level with semi-quantitative Reverse 
Transcription PCR using the selected clones, as can be seen in Figure 4.15. 
 
 
 
 
Figure 4.14 : shRNA knockdown of FAM134B is effective, especially in clones 59-11 and -12. 
Figure 4.15: shRNA silencing of FAM134B is also visible at 
the mRNA level in clones 59-11 and -12. 
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Figure 4.16: FAM134B-silenced Snu449 cells displayed an altered morphology in culture. 
4.3.5.2 FAM134B-silenced Snu449 cells display an altered morphology in 
culture 
As seen in Figure 4.16, the Snu449 shFAM134B 59-11 and 59-12 clones 
displayed a more elongated morphology in cell culture that is typical of the 
more mesenchymal-like, poorly differentiated HCC cell lines, compared to 
the more round and grouped morphology of the more epithelial-like cell lines.  
 
 
 
 
 
 
4.3.5.3 Despite having an elongated, more mesenchymal-like appearance in 
culture, FAM134B knockdown Snu449 cells did not have an increase in 
Vimentin levels or migration capacity 
We had previously suspected that the elevated levels of FAM134B protein in the 
more mesenchymal-like cell lines may be a consequence of EMT, and in PLC cell 
lines, induction of EMT and increase in Vimentin appeared to cause some increase in 
FAM134B levels. Therefore, it was surprising to observe a more elongated, 
mesenchymal-like appearance in the FAM13B knockdown Snu449 cells.  We 
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investigated further by assessing the Vimentin expression levels, but there was no 
significant increase, as seen in Figure 4.17. 
 
 
 
 
 
 
 
We also wished to asses any changes in the migratory capacity of the FAM134B-
silenced Snu449 cells with a wound-healing assay.  Interestingly, as seen in Figure 
4.18, the FAM134B-silenced Snu449 cells had a slightly reduced migratory capacity.     
Figure 4.17:  Vimentin levels are not significantly increased in 
FAM134B knocked-down Snu449 cells. 
Figure 4.18:  FAM134B-silenced Snu449 cells had poorer survival and migratory capabilities 
under serum starved conditions that inhibited proliferation. 
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Figure 4.19:  FAM134B-silenced Snu449 cells have poorer survival 
capabilities under serum starvation conditions. 
In the scratch assay shown in Figure 4.18, 24 hours after the cells were plated, the 
medium of the cells were switched from 10% serum to 0.05% serum in order to 
prevent proliferation of the cells so that cell movement could be detected accurately.  
It caught our attention that there was more cell death in the FAM134B-silenced 
Snu449 cells under serum starvation conditions, which was validated with an SRB 
experiment as follows. 
4.3.5.4 FAM134B-silenced Snu449 cells have poorer survival capabilities under 
serum starvation conditions 
The sulforhodamine B (SRB) colorimetric assay was used to establish survival rates 
of FAM134B-silenced Snu449 cells versus control cells under cytotoxic conditions.  
SRB is a red, water-soluble, fluorescent dye that is used for the quantification of 
cellular proteins of cultured cells as a means of determining cell density [45].  
In the graph in Figure 4.19, the survival ratio of each cell type was determined by 
considering the cell density at 10% serum as the 100% survival mark of that 
particular cell type.  As can be seen in the graph, FAM134B-silenced Snu449 cells 
have poorer survival capabilities under serum starvation conditions. 
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Figure 4.20:  Snu449 cells have a significantly high resistance to thapsigargin. 
4.3.6 Effects of FAM134B Knockdown on Cytotoxicity of 
Different Drugs  
In this section, the SRB colorimetric assay was utilized in order to determine survival 
rates of different cell types after 72 hours of treatment with different cytotoxic drugs 
and conditions, and half maximal inhibitory concentration (IC50) values were 
determined for each treatment for each cell type.  The assays were performed in 96-
well plates in triplicates. 
4.3.6.1 Snu449 cells have a very high resistance to thapsigargin 
As previously cited, thapsigargin is an inhibitor of the sarco-endoplasmic reticulum 
Ca
2+
 ATPase (SERCA) pumps (encoded by the ATP2A3 gene) found on the 
endoplasmic reticulum membrane.  Thapsigargin prevents the uptake of cytosolic 
calcium by the ER, causing depletion of calcium in the ER lumen and increase of 
calcium in the cytosol [43].  
Analysis of the cytotoxicity of thapsigargin on the selected HCC cell lines revealed 
that Snu449 cells had the highest resistance to apoptosis induced by thapsigargin, as 
seen in Figure 4.20. 
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4.3.6.2 Knockdown of FAM134B caused a dramatic loss of Thapsigargin 
resistance in Snu449 cells, indicating a calcium-associated function for 
the FAM134B protein 
The effect of FAM134B silencing on the thapsigargin resistance capability of 
Snu449 cells was very dramatic; while the half maximal inhibitory concentration 
(IC50) was about 92.61nM for Snu449 Scrambled 4 control cells, the half maximal 
inhibitory concentration of thapsigargin was as little as 5.33nM in Snu449 
shFAM134B 59-11 cells, as seen in Figure 4.21. 
 
This dramatic loss of thapsigargin resistance upon silencing of FAM134B indicated 
that the FAM134B protein may have a role that is associated with calcium levels in 
the cell; FAM134B may either interact with the calcium pumps on the ER membrane 
to prevent the channel’s inhibition by thapsigargin, or it may play a role in adapting 
cellular functions to conditions of high cytosolic calcium and low ER calcium. 
Further experimenting with the cytotoxicity of different drugs to FAM134B-silenced 
Snu449 cells provided additional support for a specific, calcium-related function for 
FAM134B. 
Figure 4.21:  Silencing of FAM134B causes a dramatic decrease in thapsigargin resistance of 
Snu449 cells. 
54 
 
4.3.6.3 Knockdown of FAM134B also caused a dramatic loss of Adriamycin 
resistance in Snu449 cells 
Adriamycin, or Doxorubicin, is a DNA intercalating agent that induces apoptosis 
primarily by causing DNA damage, but interestingly, it was also demonstrated to 
interfere with the sarco-endoplasmic calcium pumps of the cell, which was best 
studied in cardiac muscle cells, for which calcium signaling has vital roles [46].   
Remarkably, FAM134B knocked-down Snu449 cells also demonstrated a very 
significant loss of Adriamycin resistance, as shown in Figure 4.22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22:  Silencing of FAM134B drastically reduces Adriamycin resistance in Snu449 cells 
both in higher ug/ml (top) and lower ng/ml (bottom) concentrations. 
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4.3.6.4 Tunicamycin resistance is not significantly affected by the silencing of 
FAM134B 
Tunicamycin is an antibiotic mixture that causes ER stress through preventing N-
glycosylation of nascent peptides in the ER.  
SRB assays on the shRNA FAM134B knock-down Snu449 cells showed no effect of 
loss of FAM134B expression on the cytotoxicity of tunicamycin to Snu449 cells, as 
shown in Figure 4.23.   
 
This result draws further attention to the likelihood of a specifically calcium-related 
function for the FAM134B protein, because tunicamycin is also a very potent ER 
stress inducer like thapsigargin, however, the cytotoxicity of tunicamycin does not 
seem to be affected by loss of FAM134B expression.  Therefore, FAM134B is likely 
to have a role that is specifically related to the calcium pumps on the ER membrane 
rather than ER stress in general, since resistance to thapsigargin and Adriamycin are 
both severely altered, and these two drugs are known to inhibit the ER calcium 
pump. 
Figure 4.23:  Tunicamycin cytotoxicity is not affected by the silencing of FAM134B. 
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Figure 4.24:   FAM134B silencing enhances antitumor activity of TGF-β. 
Figure 4.25:  FAM134B silencing only slightly enhances EtOH-induced cell death. 
4.3.6.5 FAM134B silencing enhances antitumor activity of TGF-β 
TGF-β causes G1 arrest and senescence in HCC cell lines, leading to an antitumor 
activity, as demonstrated previously by our group [47].  Figure 4.24 shows that 
FAM134B-knocked-down Snu449 cells had reduced survival rates. Intriguingly, 
TGF-β was also shown to increase intracellular levels of Ca2+, as well as inositol 
triphosphate (IP3) which plays key roles in calcium homeostasis [48] 
 
 
 
 
 
 
 
4.3.6.6 FAM134B silencing only slightly enhances EtOH-induced cell death 
In order to detoxify ethanol, hepatocytes can double the surface area of their smooth 
ER for a few days [49].  Here, it was investigated whether FAM134B was essential 
in this process of overcoming an EtOH challenge, and there seemed to be some 
effect.  
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4.3.6.7 Knockdown of FAM134B does not affect resistance of Snu449 cells to 
the anti-cancer drugs 5-fluorouracil and camptothecin 
5-Fluorouracil (5-FU) is a drug pyrimidine analog that inhibits thymidylate synthase, 
leading to DNA damage [50].  Camptothecin binds and stabilizes the topoisomerase I 
and DNA complex that forms during DNA replication and transcription, causing 
DNA damage and apoptosis [51].  SRB assays did not reveal a significant difference 
between the survival rates of FAM134B-silenced Snu449 cells compared to 
scrambled control, as seen in Figure 4.26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.26:  FAM134B silencing does not affect resistance to 5-fluorouracil and 
camptothecin induced cytotoxicity. 
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4.3.6.8 Knockdown of FAM134B does not significantly affect survival rates 
under oxidative stress induced by hydrogen peroxide  
Hydrogen peroxide (H2O2) treatment gives rise to the free radical OH, which is a 
Reactive Oxygen Species (ROS) known to cause oxidative stress, lipid peroxidation, 
ER stress, and ultimately, apoptosis in cancer cells [52]. Therefore, possible 
differential survival rates under H2O2 treatment were also investigated to observe any 
difference in the FAM134B silenced cells in coping with oxidative stress.  As seen in 
Figure 4.27, there was no significant difference in the survival rates of FAM134B 
knocked-down Snu449 shFAM134B 59-11 cells and Snu449 Scrambled 4 control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.27:  Silencing of FAM134B does not significantly affect survival rates 
under oxidative stress induced by H2O2.  
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Figure 4.28:   Protein candidates that are predicted to phosphorylate FAM134B isoform 1. 
FAM134B_ISO1 
4.4 Proteins predicted to phosphorylate FAM134B isoforms 
Our western blot results indicated that the FAM134B protein may be subjected to 
post-translational modifications such as phosphorylation.  And our SRB results 
demonstrated that FAM134B protein may be important in cell survival under several 
forms of cytotoxic drugs, such as tunicamycin.  Further experimental work will need 
to performed in order to understand the function of the FAM134B protein, but here, 
an online predictive tool was utilized. 
The Motif Scan tool found on the Scansite website (scansite.mit.edu) developed by 
Massachusetts Institute of Technology [53] was utilized in order to predict protein 
candidates that may be phosphorylating the two isoforms of the human FAM134B 
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Figure 4.29: Protein candidates that are predicted to phosphorylate FAM134B isoform 2. 
FAM134B_ISO2 
protein.  This tool contains a database of the short consensus target sequences of 
several well-known kinases, and identifies these short regions on a protein sequence 
query.   
Intriguingly, as seen in Figure 4.28, ERK1 kinase, ATM kinase, Calmodulin 
dependent kinase 2, Casein kinase and 14-3-3 mode 1 are among the proteins 
predicted to phosphorylate FAM134B isoform1, with very high stringency scores. A 
percentile score less than 0.2 is considered to have a high stringency, and several 
research papers have utilized the Scansite tool as a starting point and have managed 
to validate these predictions experimentally [54]. 
ERK1 kinase is particularly very interesting as a possible kinase that may be 
phosphorylating FAM134B.  SRB assays using the FAM134B knockdown cells have 
demonstrated that the FAM134B protein is likely to have a function that is essential 
for cell survival under ER stress, especially when calcium channels are inhibited.  
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Snu449 cells are known to have a high endogenous c-Src activity, promoting 
carcinogenesis through the Src/PI3K/Akt pathway [33] [34].  It is also known that 
the PI3K/Akt and MEK1/ERK pathways cross-talk and regulate survival under ER 
stress [25].  Therefore, it would be very interesting to experimentally determine 
whether FAM134B isoform 1 is indeed phosphorylated by ERK1 kinase.  
Figure 4.29 demonstrates that, ATM kinase, Calmodulin dependent kinase 2 and 
Casein kinase 2 may also be among the kinases that may phosphorylate FAM134B 
isoform 2. 
The other predicted candidates are also very interesting. Calmodulin dependent 
kinase 2 is a kinase that is essential for Ca
2+
 homeostasis as Calmodulin is a calcium 
modulated protein that transduces Ca
2+
 signals in the cell. 14-3-3 mode 1 is involved 
in the regulation of Akt, Raf1, Bad, Bax and Cdc25.  ATM kinase targets p53, CHK2 
and H2AX, aiding in DNA damage response, and is involved in cell cycle arrest and 
apoptosis mechanisms in response to DNA damage. Mutants of Casein Kinase 2 
have impaired sperm development, which is particularly interesting since FAM134B 
protein is most dominant in testes tissues in humans and mice [19] [36] and this 
kinase is involved in cell cycle control, DNA repair, circadian rhythm, and the Wnt 
pathway.  
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5. DISCUSSION AND CONCLUSION 
Perhaps the most interesting finding during the course of this study was the dramatic 
loss of thapsigargin and adriamycin resistance in Snu449 cells upon silencing of 
FAM134B.  This result, as well as the other conclusions will be summarized and 
discussed in detail in this chapter. 
5.1 Domains and Motifs found on the FAM134B Protein 
Based on the domains and motifs on the protein products, FAM134B may be an ER-
associated, reticulon-like, organelle shaping protein that may be subject to 
phosphorylation. FAM134B showed a perinuclear staining like that of calnexin, 
which may further implicate localization on the ER.  Motif analyses indicated that 
the FAM134B protein has consensus sequence motifs that may be targeted for 
phosphorylation by important kinases such as ERK1 kinase, ATM kinase, 
Calmodulin dependent kinase 2, Casein kinase and 14-3-3 mode 1.  These results 
may create a slightly clearer picture when combined with the SRB results that 
implicate a role for FAM134B in resistance to cytotoxic agents that inhibit calcium 
pumps on the ER membrane, and will be discussed in detail, along with further 
analyses that needs to be performed. 
5.2 FAM134B and ER Stress 
In mouse liver tissues, ER stress induction for 8 hours with tunicamycin does not 
cause an increase in FAM134B mRNA or protein levels.   ER stress induction in 4 
HCC cell lines with 3 different ER stress inducers for 3 different time points did not 
appear to cause a significant elevation in FAM134B mRNA and protein levels, 
except for 6 hours of 5mM DTT treatment on Snu449 cells, which also appeared to 
induce apoptosis.   
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5.3 FAM134B and Epithelial-to-Mesenchymal Transition 
In HCC cell lines, the poorly-differentiated, more mesenchymal-like cell lines 
demonstrated higher FAM13B levels compared to the well-differentiated, more 
epithelial-like cell lines.  EMT induction with TGF-β treatment resulted in a dramatic 
increase in the vimentin levels and mesenchymal-like morphology of PLC cells, 
accompanied by an increase in FAM134B protein levels.  
Snu449 cells in which FAM134B was silenced through shRNA interference 
exhibited an altered morphology in cell culture, having a more elongated appearance 
compared to parental Snu449 cells and Snu449 cells transfected with Scrambled 
shRNA controls.  However, the FAM13B silenced cells did not have a significant 
elevation in their vimentin levels.  In fact, the FAM134B knockdown cells 
demonstrated less motility in a wound healing assay. 
The loss of migratory capabilities upon knockdown of FAM134B may be the most 
interesting result related to EMT, since FAM134B levels are also observed to be 
elevated in the more mesenchymal-like HCC cell lines compared to the more 
epithelial-like ones.  Previous research in our lab demonstrated that overexpression 
of FAM134B does not confer mesenchymal characteristics to Huh7 cells such as 
elevated vimentin expression [40].   
Therefore, FAM134B may not be a cause but a result of EMT, and may be allowing 
cells that have gone through epithelial-to-mesenchymal transition to adapt to this 
new state, perhaps through shaping the ER membrane to a state that allows the 
mesenchymal state to persist, because when FAM134B is silenced, the cells lose 
their migratory capabilities.  
5.4 FAM134B and Survival under Cytotoxic Stimuli  
Knockdown of FAM134B in Snu449 cells resulted in a dramatic loss of resistance to 
thapsigargin and adriamycin treatment, which are both known to inhibit the 
functioning of the sarco-endoplasmic reticulum ATPases that constitute a channel on 
the ER membrane which is responsible for sequestering calcium from the cytosol and 
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regulating calcium homeostasis both in the ER and in the cytoplasm.  With 
tunicamycin, the half maximal inhibitory concentration (IC50) for Snu449 
Scrambled4 cells was ~93nM, while only ~5nM was the half maximal inhibitory 
concentration for Snu449 shFAM134B 59-11 cells.  With lower doses of adriamycin, 
the IC50 value for Snu449 Scrambled4 cells was ~747ng/ml, while it was only 
~46ng/ml for Snu449 shFAM134B 59-11 cells.  These results show a drastic 19 fold 
decrease in resistance to thapsigargin, and 16 fold reduction in resistance to 
adriamycin in FAM134B-silenced Snu449 cells.  
The TGF-β cytotoxicity results were also very interesting, showing a 20 fold 
difference.  With the TGF-β treatments, the IC50 value for Snu449 Scrambled4 cells 
was ~107ng/ml, while only ~5ng/ml TGF-β was enough for 50% inhibition in 
Snu449 shFAM134B 59-11 cells. Combined with the EMT-related observations, this 
result may implicate that while the control Snu449 cells are in a more mesenchymal-
like state where TGF-β is not cytotoxic but is triggering other consequences in the 
cell, the FAM134B-silenced Snu449 cells are no longer able to accommodate a 
mesenchymal-like state and TGF-β treatment ends up being cytotoxic, probably 
causing cell cycle arrest and apoptosis, which may need to be further established. 
FAM134B silencing also had some influence on cell survival under tunicamycin and 
ethanol treatment, inducing a 2 to 3 fold change in IC50 values. With tunicamycin, 
the IC50 value for Snu449 Scrambled4 cells was ~107ng/ml, and it was ~53ng/ml for 
Snu449 shFAM134B 59-11 cells.  With ethanol, the IC50 value for Snu449 
Scrambled4 cells was ~166mM, and it was ~72mM for Snu449 shFAM134B 59-11 
cells.  These may also implicate an ER-related role for FAM134B since tunicamycin 
is an ER stress inducer that works through inhibition of N-glycosylation, and ethanol 
challenges the cell to increase its smooth ER capacity for detoxification [27].  
Therefore, when FAM134B is silenced, the cell may be rendered incapable of 
increasing its ER capacity to overcome these ER related challenges. 
FAM134B silencing did not have a very significant influence on the resistance of 
Snu449 cells to other cytotoxic drugs and stimuli tested, such as H2O2, camptothecin, 
and 5-FU.  Compared to the thapsigargin and adriamycin results, this may strengthen 
the hypothesis that FAM134B may specifically have a calcium related function.  
65 
 
Further experiments will need to be performed to fully confirm the effect of 
FAM134B knockdown in resistance to drugs such as Thapsigargin, and to better 
understand the function of this protein.  Some of these experiments that need to be 
performed are described in the “Future Perspectives” section. 
5.5 A Possible Relationship between the Src/PI3K and MEK1/ERK 
Pathways, the ER, FAM134B, and Calcium Homeostasis 
It is important to state that this section is speculative, and not based on any 
experimental data obtained during the course of this thesis work.  This section 
predicts the possibility of a role for FAM134B in cell survival under treatments with 
drugs such as thapsigargin that disturb calcium homeostasis, merely based on the 
knowledge available in the literature, and on the predictive online tool MotifScan.  
Further experimental research will need to be carried out in order to establish a 
function for the FAM134B protein, especially in the context of HCC. 
The influence that FAM134B appears to have on survival under ER stress, especially 
when it is induced by disruption of calcium homeostasis, guided us towards inquiring 
more about mechanisms of survival under ER stress.  A 2004 publication titled 
“Critical Role of Endogenous Akt/IAPs and MEK1/ERK Pathways in Counteracting 
Endoplasmic Reticulum Stress-induced Cell Death” investigated the mechanisms 
involved in survival under thapsigargin and tunicamycin induced ER stress.  They 
demonstrated that inhibition of PI3K and the MEK1/ERK pathways sensitized MCF-
7 and H1299 cells to thapsigargin- and tunicamycin-induced cell death, and that 
PI3K promoted survival both through Akt and through cross-talk with ERK. [25] 
This is particularly interesting because Snu449 cells, which we observed to have a 
very high resistance to thapsigargin-induced apoptosis, were demonstrated to have 
elevated levels of endogenous Src activity, according to the 2005 article, “Biology of 
SNU Cell Lines” published by Seoul National University researchers that developed 
the SNU cell lines [55], and Src is a tyrosine kinase that is upstream of PI3K/Akt.  
Therefore, an elevated Src activity may imply an elevated PI3K activity, which may 
promote the resistance of Snu449 cells to thapsigargin, through Akt and ERK.  
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As presented earlier in the results section, the online MotifScan tool of the MIT 
predicted that ERK1 kinase may be phosphorylating FAM134B protein isoform 1.  
The predictions made by this tool has been successfully confirmed with experiments 
in several publications, such as the 2011 article published by Sharpe et al. which 
demonstrates that Akt phosphorylates a component of the coat protein II that 
mediates ER-to-Golgi trafficking [54]. 
The FAM134B protein appears to be localized on the cis compartment of the Golgi 
apparatus [57], which is the side that faces the ER, and also appears to have a 
function that is associated with the calcium pumps on the ER.  Therefore, FAM134B 
may also be involved with the membrane-enclosed vesicles that are trafficked 
between the ER and the Golgi apparatus.  Coat-protomer, or coatomer, proteins are 
the proteins that form the vesicles that are trafficked between the ER and the Golgi. 
COPI vesicles are responsible for transport from the Golgi back to the ER; this is 
usually performed to return misfolded proteins back to the ER because the Golgi 
apparatus has no chaperones and cannot accommodate proper protein folding.  The 
transport from the ER to the Golgi apparatus, on the other hand, is carried out by the 
COPII vesicles. [54] 
Interestingly, calcium gradients in the cytosol appear to influence the timing of the 
coating and uncoating of these vesicles that are transported between the ER and 
Golgi, as demonstrated by the article titled “A Role for Calcium in Stabilizing 
Transport Vesicle Coats” [29].   When cytosolic calcium is too high, the vesicles 
may not be able to uncoat to deliver their cargo. 
The proteolytic enzyme called calpain 8 also functions in releasing the COP vesicles 
from the Golgi, and is interestingly regulated by cytosolic calcium as well.  
Excessive cytosolic calcium makes calpain excessively active, causing proteolysis of 
non-target proteins.    
Taking these into consideration, further research has to be performed in order to 
determine the function of the FAM134B protein and to be able to place it in a 
pathway by identifying its possible upstream effectors.   
 
67 
 
6. FUTURE PERSPECTIVES 
Before a conclusion can be reached on the function of the FAM134B protein, 
especially in the context of hepatocellular carcinoma, further research has to be 
conducted.  
The effect of FAM134B silencing in resistance to drugs such as thapsigargin and 
adriamycin needs to be confirmed initially by using the other clones that have 
successfully silenced FAM134B protein levels; the Snu449 Scrambled 2 and Snu449 
shFAM134B 59-12 clones may be another pair of clones that can be used, because 
the Snu449 shFAM134B 59-12 clones also had higly reduced levels of fAM134B, as 
demonstrated in Figure 4.14. 
The impact of silencing FAM134B on resistance to cytotoxic drugs will also need to 
be further confirmed with siRNA transfection of Snu449 cells as well, because the 
process of constructing stable cell lines with shRNA transfection involves the 
selection of single cells and forming clones, and this individual cell may have 
alterations other than the silencing of FAM134B which may affect the findings, this 
is called “clonal effect”.  
Another aspect that needs to be answered is whether FAM134B confers resistance to 
apoptosis by calcium pump inhibitors through actually preventing the inhibition of 
these pumps, or by accommodating the cell to these changes in calcium homeostasis.  
If FAM134B prevents the inhibition of calcium pumps, under thapsigargin and 
adriamycin treatment, the Snu449 cells should still have a high calcium 
concentration in the ER and lower levels of calcium in the cytosol, however, if the 
inhibition of the calcium pumps is not prevented, the cells will have low ER calcium 
levels and high cytosolic calcium levels.  This can easily be established by using the 
calcium staining dye Alizarin Red.   
The possible influences of Src, PI3K, and MEK/ERK on FAM134B protein levels 
and phosphorylation levels may be analyzed by initially using the inhibitors of these 
proteins, which are PP2/PP1 or Sarcatinib for Src, LY294002 for PI3K, and U0126 
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for MEK/ERK.  Later, in order to investigate a direct interaction and phosphorylation 
of FAM134B protein by these kinases, co-immunoprecipitation and kinase assays 
would have to be performed.   
Other HCC cell lines that may have endogenously hyperactive Src/PI3K and 
MEK1/ERK pathways may also be utilized to perform the experiments we have 
performed with Snu449 cells as well.  For instance, Mahlavu cells have been shown 
to have hyper-phosphorylated Akt in previous studies, [58] therefore, Mahlavu cells 
may be a good candidate.  Knockdowns in such other HCC cell lines and pathway 
analyses using inhibitors of possible upstream kinases of FAM134B may be ideal for 
being able to generalize our results to further HCC cell lines. 
The results of these analyses may help determine the function of the FAM134B 
protein, place it in a pathway and understand how it may influence hepatocellular 
carcinoma. 
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